

1 **Ribosomal RNA 2'-O-methylation dynamics impact cell fate decisions**

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Häfner SJ^{1*}, Jansson MD¹, Altinel K¹, Kraushar ML², Andersen KL¹, Caldwell Abay-Nørgaard Z³, Fontenas M¹, Sørensen DM¹, Gay DM¹, Arendrup FS¹, Tehler D¹, Krogh N⁴, Nielsen H⁴, Kirkeby A^{3,5}, Lund AH^{1*}

Affiliations

- ¹ Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
- ² Max Planck Institute for Molecular Genetics, Berlin, Germany
- ³ Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
- ⁴ Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
- ⁵ Wallenberg Center for Molecular Medicine, Department of Experimental Medical Science, Lund University, Sweden

*Corresponding authors: Sophia Häfner (sophia.hafner@bric.ku.dk), Anders H. Lund (anders.lund@bric.ku.dk)

28 **Abstract**

29

30

31 Translational regulation impacts both pluripotency maintenance and cell differentiation.

32 To what degree the ribosome itself exerts control over this process remains unanswered.

33 Accumulating evidence has demonstrated heterogeneity in ribosome composition in various

34 organisms. 2'-O-methylation of rRNA represents an important source of heterogeneity, where

35 site-specific alteration of methylation levels can modulate translation. Here we explore changes

36 in rRNA 2'-O-methylation during mouse brain development and during tri-lineage

37 differentiation of human embryonic stem cells. We find distinct alterations between brain

38 regions, as well as clear dynamics during cortex development and germ layer differentiation.

39 We identify a methylation site which impacts neuronal differentiation. Modulation of its

40 methylation levels affects ribosome association of the Fragile X Mental Retardation Protein

41 and translation of WNT pathway-related mRNAs. Together, the data reveals ribosome

42 heterogeneity through rRNA 2'-O-methylation during early development and differentiation

43 and suggests a direct role for ribosomes in regulating translation during cell fate acquisition.

44

45

46 **Introduction**

47

48 Embryonic development is known to require specific and accurately dosed protein subsets with
49 utmost spatiotemporal precision, often paralleled by profound changes in cell proliferation and
50 overall protein synthesis rates (Khajuria et al., 2018; Kraushar et al., 2015; Magee and Signer,
51 2021; R. Wang and Amoyel, 2022). In particular, the formation of the mammalian nervous
52 system requires an exceptionally fine-tuned protein homeostasis in order to generate, organize,
53 and connect hundreds of neural subtypes (Baser et al., 2019; Blair et al., 2017; Kapur et al.,
54 2017; Kraushar et al., 2020), and any failure of the translation machinery derails normal brain
55 development and function (Kapur et al., 2017; Laguesse et al., 2015; Lauria et al., 2020;
56 Yamada et al., 2019). Hence, multiple layers of regulation converge during development to
57 impact gene expression output. Whereas transcriptional, posttranscriptional, and
58 posttranslational regulation have been studied in many developmental model systems
59 (Mohammed et al., 2017; Y.-C. Wang et al., 2014; B. S. Zhao et al., 2017), the role of
60 translation, and specifically the intrinsic regulatory potential of modifications to the ribosome
61 itself, remains understudied (Baser et al., 2019; Lins et al., 2022).

62

63 Nonetheless, recent technological advances, such as ribosome profiling (“Ribosome Profiling
64 of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian
65 Proteomes,” 2011), allowing for the global quantitative assessment of translation efficiency
66 have unveiled a substantial lack of correlation between the transcriptome and protein levels
67 (Y.-C. Wang et al., 2014). Notably during neurogenesis, the translational status of thousands
68 of genes changes without matching variations in mRNA levels (Blair et al., 2017), most of
69 them holding key functions in neural differentiation and function (Lins et al., 2022). These
70 observations put forward that translational regulation has a major impact on the final output of
71 gene expression. Moreover, the question how this control may be exerted on specific mRNA
72 subsets has brought ribosomes as potential control elements into the limelight (Breznak et al.,
73 2022).

74

75 In eukaryotes, a highly controlled and energy-consuming ribosome biosynthesis pathway
76 ensures the correct assembly of this huge macromolecular complex made of RNA (rRNA) and
77 proteins (RPs) (Baßler and Hurt, 2019; Khatter et al., 2015; Ramakrishnan, 2002).

78 Beyond the core ribosome, a large number of associated factors have been identified in
79 different organisms (Imami et al., 2018). Further complexity arises through post-translational

80 modification of ribosomal proteins and the large number of different rRNA modifications
81 (“Translational control through ribosome heterogeneity and functional specialization,” 2022).
82 The two most abundant rRNA modifications are pseudouridines (Ψ) and 2'-O-methylations
83 (2'-O-me) (“Translational control through ribosome heterogeneity and functional
84 specialization,” 2021). Both modifications are added to specific rRNA nucleotides by generic
85 enzymes guided by small nucleolar RNAs (snoRNAs) *via* complementary base-pairing
86 interactions. More specifically, Ψ is installed by Dyskerin and guided by box H/ACA
87 snoRNAs, and 2'-O-me executed by Fibrillarin in complex with box C/D snoRNAs (Steitz and
88 Tycowski, 1995).

89

90 Despite the inherent complexity of the ribosome, investigation into the mechanisms by which
91 translation is controlled has mainly focused on mRNA abundance, sequence, and secondary
92 structure, as well as regulation by translation initiation and elongation factors (Genuth and
93 Barna, 2018; Sternberg et al., 2009). However, over recent years, evidence has accumulated
94 suggesting that ribosomes are not generic machines but come with a considerable amount of
95 natural and pathologic variations. The sources for this diversity are manifold, and a direct
96 consequence of the abovementioned complexity (“Translational control through ribosome
97 heterogeneity and functional specialization,” 2022). As such, several studies have reported
98 variation in the RP composition through the incorporation of RP paralogs or alterations in RP
99 stoichiometry (Fusco et al., 2021; Gupta and Warner, 2014; Kondrashov et al., 2011; Shi et al.,
100 2017; Slavov et al., 2015), and their post-translational modifications (Imami et al., 2018).
101 Likewise, rRNA variation can stem from differential expression of variant rDNA alleles found
102 in the multiple rDNA clusters present in mammalian cells (Fan et al., 2022; Parks et al., 2018),
103 as well as from changes in the rRNA post-transcriptional modification profiles (Shi and Barna,
104 2015; Sloan et al., 2016; Xue and Barna, 2012). Furthermore, the observation in humans and
105 mice that genetic defects of RPs, rRNA processing genes, or ribosome biogenesis factors may
106 result in tissue-specific pathologies, termed ribosomopathies, indicates that the affected
107 ribosomes play divergent roles in different cell types (Kampen et al., 2020; Khajuria et al.,
108 2018). The establishment of ribosome heterogeneity has led to the hypothesis of functional
109 ribosome specialization, where alternating core protein composition as well as protein or rRNA
110 modifications could confer additional layers of regulation to the translation process by
111 influencing translation speed and fidelity, or by promoting the translation of specific mRNA

112 subsets (Norris et al., 2021; Shi and Barna, 2015; “Translational control through ribosome
113 heterogeneity and functional specialization,” 2021).

114

115 Using RiboMeth-seq (RMS), a high-throughput sequencing-based method that allows for the
116 simultaneous mapping and quantitative assessment of the 2'-O-me status of all rRNA residues
117 (Birkedal et al., 2014; Krogh et al., 2017), we have previously observed that about a third of
118 the 109 rRNA positions known to carry 2'-O-me in humans are fractionally methylated, i.e.
119 that not all ribosomes of a given cell or tissue carry a modification at one of these positions
120 (Jansson et al., 2021; Krogh et al., 2016). Moreover, these fractionally methylated sites in
121 particular exhibit significant differences in their methylation degree between different cell
122 types and conditions. These findings have been corroborated by studies demonstrating
123 variation of the rRNA 2'-O-me-profile during normal development in zebrafish and mice
124 (Hebras et al., 2020; Ramachandran et al., 2020), and in pathologies such as diffuse large B-
125 cell lymphoma (Krogh et al., 2020) and breast cancer (Marcel et al., 2020). Together, the data
126 suggest the existence of ribosome subtypes characterized by different 2'-O-me modification
127 patterns. Emerging experimental evidence support the notion of 2'-O-me sites facilitating
128 ribosome specialization. For instance, we have recently shown that expression of Myc results
129 in specific alterations of the ribosome 2'-O-me pattern in human cells, particularly at
130 18S:C174, which in turn impact translation of distinct mRNAs depending on their codon
131 composition (Jansson et al., 2021).

132

133 Here, we aim to understand the importance of ribosomal 2'-O-me for cell fate establishment in
134 early embryonic development and during neuronal specification. We show that the rRNA 2'-
135 O-me profile undergoes significant and profound changes during mouse embryonic and
136 postnatal brain development with dynamics at some positions being specific to certain brain
137 regions. Tracing development back to germ layer specification, we demonstrate that the
138 directed differentiation of human embryonic stem cells (hESCs) into the three embryonic germ
139 layers trigger significant differentiation type-specific 2'-O-me dynamics. The importance of
140 these dynamics is highlighted by our finding that the removal of a single, dynamic 2'-O-me
141 modification push cell fate towards the neurectoderm. This is mediated through an altered
142 translation of WNT signaling pathway members and differential association of the translational
143 regulator Fragile X Mental Retardation Protein (FMRP) in the vicinity of the modulated 2'-O-
144 me site.

145 Together, the data indicate that ribosomal RNA modification constitutes a previously
146 unrecognized and essential regulatory mechanism in regulating mammalian gene expression
147 and establishing cellular identity.

148

149 Results

150

151 Temporal and regional rRNA 2'-O-me dynamics during mouse brain development

152

153 Previously, we demonstrated the existence of 2'-O-me dynamics in cell culture models
154 (Jansson et al., 2021). To investigate whether heterogeneity and dynamics of 2'-O-me exist *in*
155 *vivo* during the transition from multipotent stem cells to differentiation, we focused on a
156 developmental system with a tightly timed sequence of neurogenesis. We performed
157 microdissection of mouse brain neocortex (CTX) during embryonic windows just prior to
158 neurogenesis (E11), throughout neurogenesis (E12.5, E14, E15.5, and E17), and in the
159 postnatal period after neurogenesis is complete (P0 and adult) (Fig. 1A). Subsequently, RMS
160 quantification of the 109 known 2'-O-me sites was performed on all samples in biological
161 triplicates.

162

163 We detect pronounced changes to rRNA 2'-O-me patterns over the course of cortex
164 development (Fig. 1B). In accordance with previous observations (Jansson et al., 2021; Krogh
165 et al., 2016), sub-stoichiometric methylation is detected at a subset of sites only, and significant
166 changes in the degree of 2'-O-me, are seen at 43 sites (Supp. Table 1). Among the variable
167 sites, most display an increase in 2'-O-me levels over the course of neocortex development.
168 Some positions transit from undetectable to fully methylated (such as 18S:U354), while other
169 sites display a late but substantial drop in methylation levels at the adult stage (for example
170 28S:G4593) (Fig. 1C). We observe hypo-methylation at embryonic stage (E11) when the
171 neuroepithelium has yet to commit to a more restricted neural stem cell lineage at E12.5, giving
172 rise to pyramidal neurons throughout subsequent embryonic stages. The 2'-O-me profile of
173 mouse embryonic stem cells (mESC) cultured *in vitro* more closely resemble the multipotent
174 E11 neuroepithelium (Fig. 1B). Interestingly, the majority of changes in the maturing
175 neocortex are sequential and progressive over time, perhaps indicating a role for rRNA
176 methylation dynamics in the stepwise acquisition of mature neuronal fate (Fig. 1B).

177

178 We next asked whether the neocortex rRNA methylation profile is aligned with other brain
179 regions in the postnatal period. Towards that, we additionally micro-dissected hippocampus
180 (HPC), cerebellum (CBM), and olfactory bulb (OFB) tissue from the same neonates and adult
181 animals used for the cortex development analysis and performed RMS (Fig. 1D, Supp. Fig.
182 1A). We identified 9 positions with significant differences between at least two brain regions

183 at the P0 stage (Supp. Table 2) and 8 positions in the adult (Supp. Table 3). Two examples in
184 the adult, 18S:G436 and 28S:C3820, are shown in Fig. 1E. Both positions displayed higher
185 methylation levels in the cortex and hippocampus compared to the cerebellum and the olfactory
186 bulb. More generally, the 2'-O-me profiles of the cortex and hippocampus, and those of the
187 cerebellum and olfactory bulb respectively form two separate clusters, consistent with their
188 divergent neurodevelopmental origins (Supp. Fig. 1B). This indicates that different neuronal
189 populations and/or distinct cellular compositions in different brain regions harbor differently
190 methylated ribosome pools.

191

192 Subsequently, we extended our comparison to the 2'-O-me profiles of the same four brain
193 regions between neonates (P0) and adult mice, revealing further marked differences (Fig. 1F,
194 Supp. Fig. 1C, Supp. Table 4). Notably, the 2'-O-me level at 28S:G4593 drops substantially
195 to almost zero in all brain regions only after birth (Supp. Table 4), demonstrating that dynamic
196 changes in 2'-O-me continue to take place in the postnatal brain. Interestingly, 28S:G4593 is
197 the only common postnatally dynamic position in all four regions, as both the number of
198 significantly changing positions (7 in CTX, 3 in OFB, 6 in CBM, 9 in HPC), and their
199 combination vary between the areas (Supp. Table 4). This reinforces the idea that the
200 acquisition of regional identity is paralleled by the establishment of a specific combination of
201 rRNA modifications and indicates a different composition of ribosome subtypes. Importantly,
202 the 2'-O-me RMS values display a remarkable reproducibility between replicates, even though
203 the samples come from independent animals. This suggests that the changes to rRNA 2'-O-me
204 are tightly regulated during mouse brain development.

205

206 Together, these findings demonstrate that significant dynamics in rRNA 2'-O-me take place *in*
207 *vivo* during mouse brain development, with modifications changing both across developmental
208 time within the same brain region, and between distinct brain regions.

209

210 **Fate-specific 2'-O-me dynamics during human ESC differentiation**

211 Our identification of dynamic rRNA 2'-O-me sites within the developmental transition from
212 multipotency to differentiation in mouse neural tissue raised the question of whether 2'-O-me
213 dynamics occur during earlier stages of stem cell commitment. We therefore analyzed
214 totipotent human ESC differentiation into the the three germ layers. For this purpose, we

215 differentiated two human ESC lines (H9 and HUES4), as well as a human induced pluripotent
216 stem cell (iPSC) line (KOLF2) into the three embryonic germ layers; endo-, meso-, and
217 ectoderm (Fig. 2A). The ectoderm differentiation, in particular, consists of a stepwise
218 restriction of pluripotency, first giving rise to early neural progenitors (eNPC), then to late
219 neural progenitors (INPC), and finally mature neurons (MN) (Fig. 2A). Appropriate generation
220 of the desired cell types over the course of differentiation was confirmed by RT-qPCR analysis
221 for a panel of pluripotency and germ layer markers (Supp. Fig. 2A, 2B) and
222 immunohistochemistry (Supp. Fig. 2C). All three cell lines differentiated as expected, with the
223 exception of ectoderm formation, where only the H9 cell line differentiated adequately and was
224 thus used for further experiments (Supp. Fig. 2D). RMS was subsequently performed on all
225 three cell lines in their pluripotent state and on their differentiated progeny (Fig. 2B, Supp. Fig.
226 3A). All three pluripotent cell lines showed very similar 2'-O-me profiles at both the
227 pluripotent and differentiated stages, indicating that the observed dynamics were robust and
228 reproducible (Supp. Fig. 3A).

229

230 Significant dynamics in 2'-O-me, at a subset of positions, were observed during the transition
231 of stem cells into endo-, meso-, and ectoderm (Fig. 2B, Supp. Table 5). Strikingly, the
232 combination of sites changing dynamically was differentiation type-specific, suggesting that
233 different compositions of 2'-O-methylated ribosome subtypes are required for divergent
234 differentiation processes (Fig. 2C, Supp. Table 5). For instance, position 18S:A576 was nearly
235 fully methylated in pluripotency and maintained this level upon endo- and mesoderm
236 differentiation, but methylation dropped significantly during ectoderm differentiation. In
237 contrast, position 18S:U354 2'-O-me levels remained close to undetectable in all samples,
238 except for ectoderm differentiation, where full methylation was gradually reached. As for
239 position 18S:G436, the methylation level was stable during ectoderm differentiation as
240 compared to pluripotent cells, but significantly decreased during endo- and mesoderm
241 generation. Finally, position 5.8S:U14 displayed a different dynamics for each type of
242 differentiation: the 2'-O-me level remains stable in mesoderm, decreases in endoderm, and
243 increases in ectoderm differentiation (Fig. 2C). Moreover, the site-specific 2'-O-me dynamics
244 observed *in vivo* during mouse brain development were largely recapitulated at the
245 corresponding positions during human neurogenesis *in vitro*. As such, both models show a
246 marked loss of methylation at position 18S:A576, and a substantial increase at position
247 18S:U354 over time (Fig. 1A-B and Fig. 2C).

248

249 Position 28S:U3904 sparked our interest, as it displayed intriguing 2'-O-me dynamics
250 specifically upon neural differentiation: its methylation levels were high in hESCs and all three
251 germ layers (RMS scores: 0.71-0.95), except for a transient drop to an RMS score of 0.36 at
252 the early neural progenitor cell (eNPC) stage, the earliest cell fate commitment intermediate
253 during ectoderm differentiation, often also referred to as “neurectoderm” (Fig. 2D). This
254 observation prompted us to speculate that this transient decrease in 2'-O-me levels might be
255 connected to, or even required for, epiblast-to-neurectoderm transition. 28S:U3904 is located
256 in the immediate vicinity of the ribosome E site in the catalytic peptidyl transferase center and
257 the ribosomal protein RPL36A(L) (Fig. 2E). 28S:U3904 2'-O-me is guided by SNORD52, and
258 in line with the drop of methylation, the expression level of SNORD52 was also decreased
259 upon neural induction, which recapitulates the epiblast-to-neurectoderm transition (in the
260 present protocol, eNPCs emerge between days 7-10) (Fig. 2F).

261

262 Altogether, the data demonstrates significant germ layer-specific alterations to the rRNA 2'-
263 O-me pattern and suggests that the ribosome population may be specifically altered to promote
264 certain translational programs related to differentiation and cell fate establishment.

265

266

267 **Loss of 28S:U3904-me in hESCs shifts cell identity towards the neural fate**

268

269 To investigate a potential causative link between specific 2'-O-me dynamics and cell fate in
270 the transition from ESC to NPC in the ectoderm lineage, we manipulated the methylation levels
271 of position 28S:U3904 by modulating the expression of the associated snoRNA guide. The
272 genomic locus of SNORD52 is located in the third intron of a long noncoding RNA (lncRNA)
273 of unknown function, *SNHG32* (Supp. Fig. 4A). This lncRNA hosts an additional snoRNA in
274 its first exon, SNORD48, which guides the positioning of 2'-O-me at 28S:C1868 (Supp. Fig.
275 4A and 4B). With the striking exception of ectoderm differentiation, the 2'-O-me dynamics at
276 these two positions were comparable (Supp. Fig. 4C). In addition, *SNHG32* was expressed at
277 very low steady state levels in all cell types examined here, while SNORD48 levels are high,
278 and SNORD52 displays moderate expression (Supp. Fig. 4D), thus arguing for a differential
279 regulation of host genes and snoRNAs.

280

281 Using CRISPR-Cas9 editing (Supp. Fig. 4E), we excised SNORD52 from wild-type H9 hESCs
282 (H9^{WT}) and characterized two independent full knock-out clones (H9^{52KO}) (Supp. Fig. 4F-G).
283 Complete loss of methylation at 28S:U3904 was confirmed by RMS (Supp. Fig. 4H).
284 Several CRISPR-negative clones (having undergone the exact same procedure as the H9^{52KO}
285 clones but without a successful deletion) were analyzed in parallel and referred to as H9^{CTRL}
286 (Supp. Fig. 4F).
287 Although cultured under the same stringent ESC conditions as the H9^{WT} cells and the H9^{CTRL}
288 clones, the H9^{52KO} clones displayed marked morphological differences compared to the former.
289 They exhibited features characteristic of eNPCs, such as small neurite outgrowths (Fig. 3A).
290 Moreover, H9^{52KO} cells displayed lower proliferation rates compared to the wild-type (Supp.
291 Fig. 5A). Strikingly, while both H9^{52KO} clones stained positive for the early neural transcription
292 factor *PAX6*, expression of the pluripotency marker *OCT4* was markedly reduced in
293 comparison to H9 wild type and H9^{CTRL} cells (Fig. 3B). Marker gene profiling by qRT-PCR of
294 stemness and differentiation markers confirmed that the H9^{52KO} clones expressed decreased
295 levels of several pluripotency marker genes, particularly *OCT4* and *NANOG*. In contrast, they
296 displayed upregulation of a subset of ectoderm-specific markers, such as *NESTIN* and *SOX1*
297 (Fig. 3C). These findings suggest that the loss of 28S:U3904 2'-O-me shifted the cellular
298 identity of hESCs towards a neural fate. H9^{52KO} cells seem to adopt an identity of NPCs, where
299 the levels of 28S:U3904 are naturally lowest (Fig. 2D). This would also explain the slight
300 change in RMS score seen at positions 28S:A1310 and 28S:A3846 in the H9^{52KO} compared to
301 H9^{WT} (Supp. Fig. 4H), given that these display a decrease and an increase in RMS score
302 respectively during neurogenesis (Fig. 2B).
303
304 To investigate the effect of manipulating 28S:U3904 2'-O-me levels on differentiation and cell
305 fate decision making, we subjected H9^{WT}, H9^{CTRL}, and H9^{52KO} cells to directed differentiation
306 into the three embryonic germ layers. Upon ectoderm differentiation, H9^{WT} and H9^{CTRL} cells
307 formed a dense monolayer patterned by neural rosettes, staining positive for ZO1 (Fig. 3D),
308 typical for early forebrain progenitors, which is the expected default patterning in the absence
309 of any added patterning factors (Pankratz et al., 2007). In contrast, H9^{52KO} cells grew less
310 densely and did not form neural rosettes (Fig. 3D), but rapidly developed neurite-like
311 extensions and networks, and strongly expressed the eNPC and INPC marker *NESTIN* (Supp.
312 Fig. 5B), as well as the later neural markers Tuj1 (β -tubulin III) (Fig. 3E) and MAP2 (Supp.
313 Fig. 5B) well in advance compared to H9^{WT}.

314
315 Marker gene expression profiling illustrated that on day 7 of ectoderm induction, H9^{WT},
316 H9^{CTRL}, and H9^{52KO} cell lines had effectively shut down pluripotency markers, and selectively
317 up-regulated ectoderm-related genes (Fig. 3C, right). In contrast, H9^{52KO} cells displayed higher
318 levels of *SOX1*, *NESTIN*, and *MAP2*, but lower levels of *SOX10*, *PAX6*, and *DLK1*.
319 Interestingly, the H9^{52KO} cells displayed higher levels of *PAX6* at day 0, which remained
320 relatively stable and seemed refractory to the transient upregulation of *PAX6* between days 3-
321 5 as seen in H9^{WT} and H9^{CTRL} cells (Supp. Fig. 5C). Moreover, several genes failed entirely to
322 be upregulated in the H9^{52KO} cells, including *OTX2*, *LHX2*, and *SOX10* (Supp. Fig. 5C). In
323 addition, H9^{52KO} cells showed incomplete or failed endo- and mesoderm differentiation upon
324 induction of these two germ layers and instead the cells formed atypical, tridimensional
325 structures (Supp. Fig. 5D). Endoderm and mesoderm markers, like *CER1* or *T/BRACHYURY*,
326 were either absent or displayed delayed upregulation (Supp. Fig. 5E and F). H9^{52KO}-derived
327 endoderm also displayed the aberrant expression of the ectoderm marker *SOX1* (Supp. Fig.
328 5E).

329
330 To assess if increased 2'-O-me levels at 28S:U3904 in hESCs would also impact cell identity,
331 we overexpressed SNORD52 from an EGFP intron in H9^{WT} and characterized two H9^{52OE}
332 clones. Stable expression of EGFP was verified at the ESC stage (Supp. Fig. 6A) and upon
333 differentiation (Supp. Fig. 6B). As expected, we observed higher expression levels of
334 SNORD52 at the ESC stage and throughout differentiation (Supp. Fig. 6C), and 2'-O-me levels
335 at position 28S:U3904 were increased relative to the H9^{WT} under hESC conditions (Supp. Fig.
336 6D). Despite restoring 2'-O-me levels at 28S:U3904, re-introduction of SNORD52 into the
337 H9^{52KO} cells did not revert them to the ESC stage, but rather induced growth arrest and terminal
338 neural differentiation (Supp. Fig. 5G). Although the expression of germ layer-specific markers
339 (Supp. Fig. 6E) suggest that H9^{52OE} cells are competent for differentiation into all three germ
340 layers, the cells differed from H9^{WT} specifically for ectoderm differentiation. Notably, the cells
341 did not form neural rosettes (Supp. Fig. 6F). Moreover, H9^{52OE} cells expressed some marker
342 genes, such as *OTX2*, at higher levels than H9^{WT}, which the H9^{52KO} cells failed to upregulate
343 or expressed at low levels, (Supp. Fig. 6G).

344
345 These results indicate that abrogation of 2'-O-me at 28S:U3904 in hESCs suffices to drive the
346 cells out of pluripotency and towards a neural cell fate, and potentially modulate the neurogenic
347 potential.

348

349

350 **Loss of 2'-O-me at 28S:U3904 does not impact ribosome biogenesis**

351

352 Installment of certain rRNA modifications, including 2'-O-me, are required for accurate
353 ribosome biogenesis and assembly, generally through stabilizing local ribosome structure
354 (Liang et al., 2007; Polikanov et al., 2015; Sloan et al., 2016). Northern blot analysis for the
355 different rRNA intermediates revealed no imbalance indicative of ribosome biogenesis defect
356 upon loss of 2'-O-me at 28S:U3904, although an overall reduction of processing intermediates
357 was observed in both the H9^{52KO} cells and H9^{WT}-derived eNPCs (H9^{NPC}) compared to the H9^{WT}
358 cells (Supp. Fig. 7A). This is consistent with several studies describing significant variations
359 in both ribosome numbers per cell and overall translation during neural differentiation (Baser
360 et al., 2019; Blair et al., 2017). Indeed, a peptide synthesis assessment *via* O-propargyl-
361 puromycin (OPP) incorporation showed reduced global translation in H9^{NPC} and H9^{52KO} as
362 compared to H9^{WT} cells, with the H9^{52KO} levels being similar to those of the H9^{NPC} (Supp. Fig.
363 7B).

364

365 Given that both ribosome and translation levels are comparable between H9^{NPC} and H9^{52KO}
366 cells, we assume that the decrease in ribosome numbers that we observe in the H9^{52KO} cells is
367 rather a consequence of the shift towards the neural fate than the result of a biogenesis defect,
368 which fits previously reported observations (Chau et al., 2018).

369

370 **28S:U3904 2'-O-me levels influence long-term neural cell identity**

371

372 Following on from the clear bias towards neuroectoderm differentiation observed in H9^{52KO}
373 cells, we proceeded to further characterize the neurogenic potential of H9^{52KO} cells by
374 differentiating the cells into mature neurons, alongside H9^{WT} and H9^{52OE} -derived NPCs
375 (H9^{52OE-NPC}). Neural maturation was allowed for 50 days and was expected to produce
376 primarily forebrain-type neurons and glia (Pankratz et al., 2007). In addition to morphology
377 monitoring, the expression of a broad panel of brain region-specific markers was assessed by
378 RT-qPCR at several time-points. Two weeks into the maturation phase, the H9^{52KO} cells
379 consistently developed a distinct morphological phenotype as compared to the H9^{WT} and
380 H9^{52OE} cells. While H9^{WT} and H9^{52OE} cells formed a homogeneous neural network, the H9^{52KO}
381 cells grew first into a dense monolayer, then formed multiple circular cavities rimmed by thick

382 borders with cilia-like cell protuberances (Fig. 4A). Gene expression analysis at the early
383 neural induction phase (day 3 and 7) showed a marked suppression of forebrain-associated
384 genes (*OTX2*, *OTX1*, *FEZF1*, *LHX2* and *SIX3*) and concomitant induction of hindbrain genes
385 (*GBX2*, *HOXA1*, *HOXA2*, *EN1* and *OTP*), as well as induction of roof plate marker *PAX7* in
386 the H9^{52KO} cells compared to the H9^{WT} cells (Fig. 4B).

387

388 Terminal maturation of the cultures further revealed the emergence of *TTR*⁺/*OTX2*⁺/*MAP2*-
389 choroid plexus cells in the H9^{52KO} but not the H9^{WT} cultures, which is consistent with a H9^{52KO}-
390 induced shift in neural patterning from forebrain towards dorsal hindbrain fates (Rifes et al.,
391 2020) (Fig. 4C).

392

393 H9^{52OE} cells in turn displayed an expression pattern similar to the one of H9^{WT} cells during
394 early differentiation time points, but assumed a more posterior gene signature at the mature
395 stage, indicating a diencephalon-like identity (Fig. 4B).

396

397 Altogether, the data indicate that the loss of 2'-O-me at 28S:3904 at the stem cell stage not
398 only prompts the cells to shift to an NPC-like nature, but also programs them for terminal
399 maturation into hindbrain neural cells, while the gain of 2'-O-me at 28S:3904 promotes
400 differentiation into diencephalon cells (Fig. 4D).

401

402

403 **2'-O-me at 28S:U3904 influences translation of mRNAs involved in WNT pathway**

404

405 To investigate whether the methylation status of 28S:U3904 might influence the translation of
406 specific mRNAs, and thus explain the early shift in cell identity in SNORD52 mutants, we
407 performed ribosome profiling of H9^{WT} and H9^{52KO} cells under ESC culture conditions (Supp.
408 Fig. 8A-D). Detected transcripts were categorized depending on their differential regulation in
409 H9^{52KO} cells into those with significant differences in mRNA expression (transcription only);
410 ribosome occupancy (translation only); both transcription and translation, opposite changes, or
411 no change. The majority of changes (6615 transcripts) fell into the class of concordant changes
412 in transcription and translation (Fig. 5A). Fitting previous observations, most transcriptionally
413 upregulated genes in the H9^{52KO} cells were related to neural cell identity or function (Supp. Fig.
414 8E), thus confirming that the H9^{52KO} cells indeed shifted towards neuroectoderm. Interestingly,
415 a subset of transcripts (1509) was significantly changed at the level of translation only (Fig.

416 **5A**). 708 transcripts displayed decreased translation (TL-DN) in the H9^{52KO} cells and gene
417 ontology (GO) analysis revealed that these transcripts related primarily to translation and
418 ribosome biogenesis, including ribosomal proteins (**Supp. Fig. 8F**). 801 transcripts were
419 translationally upregulated (TL-UP) in the H9^{52KO} cells, and the most enriched, statistically
420 significant GO category corresponded to genes related to the WNT signaling pathway (**Fig.**
421 **5B**). The WNT/ β -catenin pathway plays a complex role in pluripotency and lineage
422 commitment, sometimes taking on opposite functions depending on the spatiotemporal context
423 (de Jaime-Soguero et al., 2018). On the one hand, WNT signaling is required for the induction
424 and maintenance of stemness (de Jaime-Soguero et al., 2018), on the other hand, differentiation
425 comes with the release of β -catenin from the cellular membrane (Sierra et al., 2018) and a surge
426 of WNT transcriptional activity (Faunes et al., 2013; Sierra et al., 2018), which notably is
427 required for neural induction (Mulligan and Cheyette, 2012; Otero et al., 2004) and rostro-
428 caudal neural tube patterning (Fang et al., 2019; Rifes et al., 2020).

429

430 We assessed canonical WNT activity using the TOP/FOP luciferase reporter assay (Barolo,
431 2006). In line with the findings above, WNT activity was markedly higher in the H9^{52KO} cells
432 compared to the H9^{WT} and H9^{52OE} under hESC conditions (**Fig. 5C**). Moreover, upon a neural
433 induction time course, the induction of WNT activity was markedly lower in the H9^{52OE} cells
434 compared to the H9^{WT} (**Fig. 5D**). Release of β -catenin from the cell membrane, where it is
435 found in a complex with the pluripotency factor OCT4, and its translocation to the cytoplasm
436 and nucleus is an additional indicator of canonical WNT pathway activation (Faunes et al.,
437 2013; Sierra et al., 2018). For this reason, we stained H9^{WT}, H9^{52KO}, and H9^{52OE} cells under
438 ESC culture conditions for β -catenin. Levels were higher and β -catenin localization
439 significantly more cytoplasmic and nuclear in the H9^{52KO} cells compared to the two other cell
440 lines, where the staining was mainly detected at the cell membrane and was lowest in the
441 H9^{52OE} cells, further supporting the finding that H9^{52KO} cells have activated canonical WNT
442 signaling (**Fig. 5E & F**).

443 Western blotting furthermore confirmed the translational upregulation of WNT target genes in
444 H9^{52KO} found by ribosome profiling, such as *RECK* and *CITED1* (**Fig. 5G**).

445

446 Hence, the data supports the notion that the methylation status of 28S:U3904 specifically
447 impacts on the capacity of the ribosome population for translating specific mRNAs including
448 those related to the WNT pathway.

449

450

451 **Ribosomes lacking 2'-O-me at 28S:U3904 display increased FMRP binding**

452

453 To explore whether there are any differences in proteins associated with the ribosomes in H9^{WT},
454 H9^{52KO}, and H9^{NPC} cells, we purified ribosomes from 80S (monosome) and polysome fractions
455 from each cell type and analyzed them by mass spectrometry (Supp. Table 7). In order to
456 examine proteins most likely to be truly associated with the ribosome and remove the majority
457 of contaminants present throughout the sucrose gradients, the detected proteins were filtered
458 using a list of ribosome-interacting proteins derived from a previous study of two human cell
459 lines (Imami et al., 2018) (Supp. Table 8, Supp. Table 9).

460 Overall, more proteins were found significantly associated with ribosomes from H9^{WT}
461 compared to either H9^{52KO}, or H9^{NPC} cells (Fig. 6A, Fig. 6B). These included many core
462 ribosomal proteins (RPs) (Supp. Table 8), suggesting the samples from H9^{WT} cells contained
463 more ribosomes in an equal amount of input material rather than indicating stoichiometric
464 changes in so many individual RPs. This is consistent with downregulated ribosome biogenesis
465 known to occur during differentiation (Breznak et al., 2022; R. Wang and Amoyel, 2022), in
466 particular the strong translational repression of RPs, whose mRNAs are characterized by 5'
467 terminal oligopyrimidine (TOP) motifs ("Ribosome Profiling of Mouse Embryonic Stem Cells
468 Reveals the Complexity and Dynamics of Mammalian Proteomes," 2011), mediated by a
469 decrease of mTOR activity (Blair et al., 2017; R. Wang and Amoyel, 2022).

470

471 We focused on proteins enriched in samples from H9^{52KO} and H9^{NPC} cells compared to H9^{WT}.
472 Among these, we found FMRP (Fragile X Mental Retardation Protein) to be significantly more
473 associated with ribosomes in H9^{52KO} (Fig. 6A), and H9^{NPC} (Fig. 6C), in both 80S and polysome
474 fractions. Moreover, FMRP is also enriched in H9^{52KO} compared to H9^{NPC} in the 80S fraction
475 (Fig. 6B). Despite having been shown to act at many levels of gene expression (Richter and X.
476 Zhao, 2021), FMRP is best known for regulating translation of mRNAs involved in
477 neurodevelopment (Li et al., 2020), leading to a crucial role in the regulation of the proliferation
478 and cell fate of neural stem cells (Luo et al., 2010). FMRP can bind both to mRNA and to the
479 ribosome, where it is assumed to bind within the intersubunit space and hamper the binding of
480 tRNA and translation elongation factors ("Fragile X Mental Retardation Protein Regulates
481 Translation by Binding Directly to the Ribosome," 2014; Khandjian et al., 1996; Richter and
482 X. Zhao, 2021).

483

484 Next, we sought to confirm the increased binding of FMRP to ribosomes devoid of 2'-O-me at
485 28S:U3904. We purified ribosomes from H9^{WT}, H9^{52KO}, H9^{52OE}, and H9^{NPC} lines through
486 sucrose cushions and probed for FMRP binding by western blot (Fig. 6D & Supp. Fig. 9). Two
487 ribosomal proteins from different subunits (RPL4 and RPS18) were used for normalization to
488 ribosome numbers. FMRP enrichment in the ribosome fraction was subsequently quantified as
489 the ratio of ribosome-bound FMRP over total FMRP levels in the cell (input). We observe a
490 strong enrichment of FMRP in the ribosome fraction of H9^{52KO} cells compared to all other cell
491 lines (Fig. 6D and 6E, Supp. Fig. 9). Of note, WT^{NPC} cells display the second-highest levels of
492 FMRP levels in the ribosome fraction, while in eNPCs derived from the H9^{52OE} cells (H9^{52OE-}
493 ^{NPC}) FMRP association was reduced, further consolidating the hypothesis that FMRP binding
494 to the ribosome is favored by the absence of 28S:U3904 2'-O-me.

495

496

497

498

499 Discussion

500

501 Correct development of complex mammalian organs, such as the brain, requires utmost
502 spatiotemporal fine tuning of gene expression programs. Accordingly, numerous regulatory
503 mechanisms have been revealed over the last decades. At the level of translation, focus has
504 predominantly been on deciphering mechanisms governing translation initiation, elongation,
505 and quality control. Yet, regulatory capacity through alterations of the rRNA modifications of
506 the ribosome itself has remained understudied.

507

508 Over the last years, solid evidence has documented considerable ribosome heterogeneity in
509 many organisms and recent studies have reported on ribosome specialization supporting
510 translation of select mRNA populations, thus indicating a more profound role for the ribosome,
511 or ribosome subtypes, in instigating specific translation programs
512 (Genuth and Barna, 2018; Jansson et al., 2021; “Translational control through ribosome
513 heterogeneity and functional specialization,” 2021). Although current technologies only allow
514 for the analysis of ribosome composition or modification patterns in bulk across a tissue or cell
515 culture, the evidence for ribosome heterogeneity strongly suggests the co-occurrence of
516 multiple ribosome subtypes. Hence, dynamic changes in heterogeneity could be interpreted as
517 an altered composition of functionally different ribosome subtypes acting in parallel within the
518 same cell.

519

520 The current study significantly corroborates the contribution of rRNA 2'-O-me variation to
521 ribosome diversity and provides conceptually novel insight into the role of differential 2'-O-
522 me in defining early stages of development and cell fate decision making during neurogenesis.
523 We demonstrate profound rRNA 2'-O-me pattern differences between brain regions, which
524 supports the hypothesis that ribosome diversification could contribute to the establishment of
525 tissue identity. The observation that significant rRNA 2'-O-me dynamics take place *in vivo*
526 during mouse brain development strongly implies biological importance. Most interestingly,
527 2'-O-me dynamics seem to persist into the postnatal period in the mouse brain. As the
528 mammalian brain undergoes extensive restructuring of neural connections, also known as
529 synaptic pruning, during the first weeks following birth, it is tempting to speculate that 2'-O-
530 me and potentially other aspects contributing to ribosome heterogeneity are important for the
531 fine-tuning of terminal cell identity in the neural network.

532

533 Tracking back to the early stages of development, we demonstrate that the directed
534 differentiation of human ES cells into the three germ layers is paralleled by significant, robust,
535 and germ layer-specific alterations to the 2'-O-me patterns of the ribosome population,
536 suggesting a role for ribosome specialization in early development and cell fate decision
537 making. The significance of these findings is further corroborated by the conservation of a
538 number of dynamic 2'-O-me positions between the mouse *in vivo* and human *in vitro* neural
539 differentiation models. This indicates an evolutionary conservation of 2'-O-me dynamics
540 during neuronal development, at least among mammals.

541

542 Having established that ribosomal RNA 2'-O-me patterns consistently change during brain
543 development and cell identity acquisition, we further demonstrated functionality by linking a
544 single 2'-O-me position to a specific differentiation process and cell fate. Removal of the 2'-
545 O-me at 28S:U3904 prompts hESCs to transition into neuroectoderm, despite being cultured
546 under restrictive stemness conditions, and compromises their ability to differentiate into the
547 two other germ layers. Furthermore, this influences the neurogenic potential of the cells by
548 changing their regional identity upon long-term maturation towards a hindbrain nature. We did
549 not observe changes in 2'-O-me levels at the murine 28S:U3904 locus in the brain development
550 model. SNORD52 is duplicated in the mouse and the locus poorly conserved. Together, this
551 could either signify an absence of dynamics in the mouse or indicate that they take place earlier
552 or in a specific subset of neurons. The fact that the re-introduction of SNORD52 into the H9^{52KO}
553 cells did not rescue the ESC phenotype is to be expected, given that the return to pluripotency,
554 or “reprogramming”, is a complicated, low-efficiency process (Takahashi et al., 2007). In
555 addition, as 28S:U3904 2'-O-me increases again when NPCs differentiate into neural precursors
556 and mature neurons, it is conceivable that expressing SNORD52, in an NPC-like context, rather
557 promotes further progress down the neural cell fate than a return to the pluripotent state.

558

559 Using ribosome profiling, we identified a set of transcripts differing only at their level of
560 translation following ablation of 2'-O-me at 28S:U3904. Most interestingly, gene ontology
561 analysis strongly indicated a role for the canonical WNT pathway, and validation experiments
562 confirmed active WNT signaling in the H9^{52KO} cells. The WNT pathway plays complex and
563 multifaceted roles in cell identity, given that it operates in self-renewal and stemness as well
564 as in lineage commitment (de Jaime-Soguero et al., 2018). De-repression or activation of WNT
565 signaling either by inhibition of GSK3 β (Shimojo et al., 2015) or activation of β -catenin
566 signaling (Otero et al., 2004) facilitates the neural differentiation of hESCs. Furthermore, WNT

567 participates in rostro-caudal organization of the neural tube (Rifes et al., 2020), axon guidance,
568 as well as synapse development and activity (Mulligan and Cheyette, 2012). Regulation of
569 WNT pathway members at the level of translation was functionally confirmed by the
570 observation that H9^{52KO} cells display strongly upregulated WNT signaling, assume an NPC-
571 like identity at the levels of morphology, gene expression, and differentiation potential, and
572 finally are biased towards a hindbrain final cell fate, fitting the WNT gradient-governed pattern
573 of the neural tube (Rifes et al., 2020).

574

575 Although we focused on the role of SNORD52 and 28S:U3904 2'-O-me during neural
576 differentiation, this does not exclude their implication in other developmental pathways. In a
577 recent study, it was shown that inactivation of SNORD52 in hematopoietic stem cells increases
578 subsequent erythroid differentiation (Nachmani et al., 2019). The hematopoietic lineages
579 derive from the mesoderm, and indeed we observe a slight increase of the 2'-O-me levels at
580 28S:U3904 upon mesoderm differentiation, although we focused on early-stage mesoderm that
581 has not yet undergone further specialization. Intriguingly, the WNT pathway also plays an
582 important role in the specification of hematopoiesis (Sturgeon et al., 2014). It would be
583 interesting to investigate the role(s) of the 28S:U3904 2'-O-me during the acquisition of non-
584 neural cell identities.

585

586 An ongoing debate in the field relates to whether ribosome heterogeneity results in ribosome
587 specialization (Ferretti and Karbstein, 2019; Mills and Green, 2017). An alternative to the
588 ribosome specialization hypothesis proposes that varying the concentration of ribosomes may
589 selectively impact different classes of mRNAs differently, without invoking specialized
590 ribosome functions - the ribosome concentration hypothesis (Khajuria et al., 2018; Mills and
591 Green, 2017). In contrast, other studies have demonstrated a specialized translation program
592 resulting from, for instance, modulation of the ribosomal protein constituents (Shi et al., 2017)
593 or rRNA modification patterns in the absence of changes to the ribosome concentration
594 (Jansson et al., 2021; McMahon et al., 2019). The two views are not necessarily contradictory,
595 and it is conceivable that some cases are regulated by a combination of specialized ribosomes
596 and ribosome numbers, although disentangling the respective contribution of both mechanisms
597 will be challenging. In the present study, loss of 2'-O-me at 28S:U3904 is accompanied by a
598 drop in ribosome number in the H9^{52KO} cells. As such, we cannot fully rule out that part of the
599 observed shift in cellular identity in our system is caused by a reduction in ribosome numbers
600 during the transition from the ESC to the neuroectoderm state. Given that this reduction to

601 similar levels is equally observed during the differentiation of WT ESCs to NPCs, it is likely
602 that the phenomenon is rather another feature of the neural cell fate commitment than its
603 triggering event.

604

605 To gain mechanistic insight into how 2'-O-methylation at 28S:U3904 can modulate translation,
606 we purified ribosomes from H9^{WT}, H9^{52KO}, and H9^{WT}-derived neuroectoderm and analyzed
607 their composition using mass spectrometry. This and subsequent validations revealed an
608 increased binding of FMRP to ribosomes purified from H9^{52KO} and neuroectoderm derived
609 from H9^{WT} cells. FMRP is a brain-enriched RNA-binding protein with a multitude of roles
610 described related to translation, mRNA transport, splicing, and RNA stability (Hale et al., 2021;
611 Richter and X. Zhao, 2021). Importantly, FMRP is also implicated in neurogenesis and neural
612 cell fate (Li et al., 2020; Luo et al., 2010) and loss of FMRP leads to fragile X syndrome
613 (Santoro et al., 2012). FMRP is generally considered a translational inhibitor and has been
614 linked to the activation of WNT signaling through the translational repression of WNT
615 inhibitors (Casinal et al., 2020; Luo et al., 2010). Such a scenario could link the enrichment
616 of FMRP in H9^{52KO} cells with a subsequent activation of WNT signaling. FMRP has previously
617 been found to interact with the 60S ribosomal subunit (Khandjian et al., 1996) and Cryo-EM
618 structural analysis from *Drosophila* locates FMRP in the ribosomal intersubunit space in close
619 vicinity of 28S:U3904 ("Fragile X Mental Retardation Protein Regulates Translation by
620 Binding Directly to the Ribosome," 2014) (Fig. 6E).

621

622 However, structural modeling predicts no direct interaction between FMRP and the 28S:U3904
623 rRNA residue, although this prediction is based on a low resolution Cryo-EM study in
624 *Drosophila*. However, both FMRP and 28S:U3904 contact the E-site tRNA and the ribosomal
625 protein RPL36A(L). RPL36A is eukaryote-specific (Kovacs et al., 2018), and one of the rare
626 cases of a ribosomal protein with an active paralog in mammals, RPL36AL (Uechi et al., 2002).
627 The paralogs differ only at the level of a single amino acid at position 38, a lysine in RPL36A
628 and an arginine in RPL36AL. The ratio of ribosomes containing RPL36A over those bearing
629 RPL36AL during development and normal homeostasis is unknown, but mutations in
630 RPL36A(L) are linked with cycloheximide resistance (Klinge et al., 2011). In the ribosome,
631 RPL36AL contacts both the CCA end of P-site bound tRNA and the translation termination
632 factor eRF1 (Baouz et al., 2009; Hountondji et al., 2014). Most interestingly, RPL36A carries
633 7 and RPL36AL 6 monomethylated residues, among them Lys38, the one variable amino acid
634 between the paralogs (Eustache et al., 2017), and the contact with the tRNA and eRF1 relies

635 on the methylation of Lys35 (Eustache et al., 2017; Hountondji et al., 2012). In addition, there
636 is evidence for fractional methylation of RPL36A(L) at positions Gln51 and Lys53, part of a
637 highly conserved motif, which gave rise to speculations that such an extensive methylation
638 pattern would likely be used for the regulation of translation or ribosome activity (Hountondji
639 et al., 2012). Given that the 28S:U3904 is located less than 5 Å proximity of the methylated
640 GGQ motif of RPL36A(L), this could point towards an intricate interplay of both rRNA and
641 RP heterogeneity through a methylation hotspot with direct effects on E-tRNA stability and
642 FMRP binding.

643

644

645 Altogether, our findings reinforce the idea that the ribosome itself is a direct regulator of
646 translation and demonstrates that modulation of the ribosome through alterations in the rRNA
647 2'O-me modification pattern contributes to directed differentiation and cell fate decision
648 making during early development.

649

650

651

652

653

654 **Acknowledgements**

655

656 The Lund lab is supported by grants from the Danish Council for Independent Research (Sapere
657 Aude program 418 3-00179B); the Novo Nordisk Foundation (NNF18OC0030656, NNF
658 0071919); the Lundbeck Foundation (R198-2015-174), and the Danish Cancer Society (R204-
659 A12532). Furthermore, this project has received funding from the European Union's Horizon
660 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement n°
661 801481 and The VILLUM Experiment Programme under the grant n° 17544 . The authors
662 would like to thank Bettina Mentz, Patrice Ménard, Anna Fossum, and Elin Josefina Pietras
663 for their technical help.

664

665 **Author contributions**

666 S.J.H. designed most experiments, collected data and drafted the article. M.D.J. carried out
667 ribosome profiling and data interpretation, and mass spectrometry data analysis. K.A. was in
668 charge of bioinformatic data analysis. M.L.K. provided mouse brain samples and insight into
669 brain development and ribosome structure. K.L.A. carried out mass spectrometry data
670 collection. Z.C. and A.N. assisted with qPCR data collection and data interpretation. M.F and
671 D.M.S. were involved in establishing cell lines. D.M.G., F.S., and D.T provided critical input
672 on the manuscript. N.K. contributed ribosome biogenesis-related experiments. H.N and A.K.
673 provided advice on data interpretation. A.H.L. and M.D.J. assisted with work conception, data
674 interpretation and drafting of the manuscript. All authors commented on the manuscript.

675

676 **Competing interests**

677 The authors declare no competing interests.

678

679 **Materials & Correspondence**

680 sophia.hafner@bric.ku.dk, anders.lund@bric.ku.dk

681

682

683 References

684

- 685 Baouz, S., Woisard, A., Sinapah, S., Le Caer, J.-P., Argentini, M., Bulygin, K., Aguié, G.,
686 Hountondji, C., 2009. The human large subunit ribosomal protein L36A-like contacts the
687 CCA end of P-site bound tRNA. *Biochimie* 91, 1420–1425.
688 doi:10.1016/j.biochi.2009.07.013
- 689 Barolo, S., 2006. Transgenic Wnt/TCF pathway reporters: all you need is Lef? *Oncogene* 25,
690 7505–7511. doi:10.1038/sj.onc.1210057
- 691 Baser, A., Skabkin, M., Kleber, S., Dang, Y., Gülcüler Balta, G.S., Kalamakis, G., Göpferich,
692 M., Ibañez, D.C., Schefzik, R., Lopez, A.S., Bobadilla, E.L., Schultz, C., Fischer, B.,
693 Martin-Villalba, A., 2019. Onset of differentiation is post-transcriptionally controlled in
694 adult neural stem cells. *Nature* 566, 100–104. doi:10.1038/s41586-019-0888-x
- 695 Baßler, J., Hurt, E., 2019. Eukaryotic Ribosome Assembly. <https://doi.org/10.1146/annurev-biochem-013118-110817>. doi:10.1146/annurev-biochem-013118-110817
- 697 Bertero, A., Pawlowski, M., Ortmann, D., Snijders, K., Yiangou, L., de Brito, M.C., Brown,
698 S., Bernard, W.G., Cooper, J.D., Giacomelli, E., Gambardella, L., Hannan, N.R.F., Iyer,
699 D., Sampaziotis, F., Serrano, F., Zonneveld, M.C.F., Sinha, S., Kotter, M., Vallier, L.,
700 2016. Optimized inducible shRNA and CRISPR/Cas9 platforms for in vitro studies of
701 human development using hPSCs. *Development* 143, 4405–4418.
702 doi:10.1242/dev.138081
- 703 Birkedal, U., Christensen-Dalsgaard, M., Krogh, N., Sabarinathan, R., Gorodkin, J., Nielsen,
704 H., 2014. Profiling of Ribose Methylations in RNA by High-Throughput Sequencing.
705 *Angewandte Chemie* 127, 461–465. doi:10.1002/ange.201408362
- 706 Blair, J.D., Hockemeyer, D., Doudna, J.A., Bateup, H.S., Floor, S.N., 2017. Widespread
707 Translational Remodeling during Human Neuronal Differentiation. *Cell Rep* 21, 2005–
708 2016. doi:10.1016/j.celrep.2017.10.095
- 709 Breznak, S.M., Kotb, N.M., Rangan, P., 2022. Dynamic regulation of ribosome levels and
710 translation during development. *Seminars in Cell & Developmental Biology*.
711 doi:10.1016/j.semcdb.2022.06.004
- 712 Casingal, C.R., Kikkawa, T., Inada, H., Sasaki, Y., Osumi, N., 2020. Identification of FMRP
713 target mRNAs in the developmental brain: FMRP might coordinate Ras/MAPK, Wnt/ β -
714 catenin, and mTOR signaling during corticogenesis. *Mol Brain* 13, 167–13.
715 doi:10.1186/s13041-020-00706-1
- 716 Chau, K.F., Shannon, M.L., Fame, R.M., Fonseca, E., Mullan, H., Johnson, M.B.,
717 Sendamarai, A.K., Springel, M.W., Laurent, B., Lehtinen, M.K., 2018. Downregulation
718 of ribosome biogenesis during early forebrain development. *eLife Sciences* 7.
719 doi:10.7554/eLife.36998
- 720 de Jaime-Soguero, A., Abreu de Oliveira, W.A., Lluís, F., 2018. The Pleiotropic Effects of
721 the Canonical Wnt Pathway in Early Development and Pluripotency. *Genes (Basel)* 9,
722 93. doi:10.3390/genes9020093
- 723 Eustache, S., Créchet, J.-B., Bouceba, T., Nakayama, J.-I., Tanaka, M., Suzuki, M., Woisard,
724 A., Tuffery, P., Baouz, S., Hountondji, C., 2017. A Functional Role for the
725 Monomethylated Gln-51 and Lys-53 Residues of the 49GGQTK53 Motif of eL42 from
726 Human 80S Ribosomes. *Open Biochem J* 11, 8–26. doi:10.2174/1874091X01711010008
- 727 Fan, W., Eklund, E., Sherman, R.M., Liu, H., Pitts, S., Ford, B., Rajeshkumar, N.V., Laiho,
728 M., 2022. Widespread genetic heterogeneity of human ribosomal RNA genes. *RNA* 28,
729 478–492. doi:10.1261/rna.078925.121
- 730 Fang, Z., Liu, X., Wen, J., Tang, F., Zhou, Y., Jing, N., Jin, Y., 2019. SOX21 Ensures Rostral
731 Forebrain Identity by Suppression of WNT8B during Neural Regionalization of Human

- 732 Embryonic Stem Cells. *Stem Cell Reports* 13, 1038–1052.
733 doi:10.1016/j.stemcr.2019.10.013
- 734 Faunes, F., Hayward, P., Descalzo, S.M., Chatterjee, S.S., Balayo, T., Trott, J., Christoforou,
735 A., Ferrer-Vaquero, A., Hadjantonakis, A.-K., Dasgupta, R., Arias, A.M., 2013. A
736 membrane-associated β -catenin/Oct4 complex correlates with ground-state pluripotency
737 in mouse embryonic stem cells. *Development* 140, 1171–1183. doi:10.1242/dev.085654
- 738 Ferretti, M.B., Karbstein, K., 2019. Does Functional Specialization of Ribosomes Really
739 Exist? *RNA* ma.069823.118. doi:10.1261/rna.069823.118
- 740 Fragile X Mental Retardation Protein Regulates Translation by Binding Directly to the
741 Ribosome, 2014. Fragile X Mental Retardation Protein Regulates Translation by Binding
742 Directly to the Ribosome. *Mol. Cell* 54, 407–417. doi:10.1016/j.molcel.2014.03.023
- 743 Fusco, C.M., Desch, K., Dörrbaum, A.R., Wang, M., Staab, A., Chan, I.C.W., Vail, E.,
744 Villeri, V., Langer, J.D., Schuman, E.M., 2021. Neuronal ribosomes exhibit dynamic and
745 context-dependent exchange of ribosomal proteins. *Nat Commun* 12, 6127–14.
746 doi:10.1038/s41467-021-26365-x
- 747 Genuth, N.R., Barna, M., 2018. The Discovery of Ribosome Heterogeneity and Its
748 Implications for Gene Regulation and Organismal Life. *Mol. Cell* 71, 364–374.
749 doi:10.1016/j.molcel.2018.07.018
- 750 Gupta, V., Warner, J.R., 2014. Ribosome-omics of the human ribosome. *RNA* 20, 1004–
751 1013. doi:10.1261/rna.043653.113
- 752 Hale, C.R., Sawicka, K., Mora, K., Fak, J.J., Kang, J.J., Cutrim, P., Cialowicz, K., Carroll,
753 T.S., Darnell, R.B., 2021. FMRP regulates mRNAs encoding distinct functions in the cell
754 body and dendrites of CA1 pyramidal neurons. *eLife Sciences* 10.
755 doi:10.7554/eLife.71892
- 756 Hebras, J., Krogh, N., Marty, V., Nielsen, H., Cavallé, J., 2020. Developmental changes of
757 rRNA ribose methylations in the mouse. *RNA Biol* 17, 150–164.
758 doi:10.1080/15476286.2019.1670598
- 759 Hountondji, C., Bulygin, K., Créchet, J.-B., Woisard, A., Tuffery, P., Nakayama, J.-I.,
760 Frolova, L., Nierhaus, K.H., Karpova, G., Baouz, S., 2014. The CCA-end of P-tRNA
761 Contacts Both the Human RPL36AL and the A-site Bound Translation Termination
762 Factor eRF1 at the Peptidyl Transferase Center of the Human 80S Ribosome. *Open*
763 *Biochem J* 8, 52–67. doi:10.2174/1874091X01408010052
- 764 Hountondji, C., Bulygin, K., Woisard, A., Tuffery, P., Créchet, J.-B., Pech, M., Nierhaus,
765 K.H., Karpova, G., Baouz, S., 2012. Lys53 of ribosomal protein L36AL and the CCA
766 end of a tRNA at the P/E hybrid site are in close proximity on the human ribosome.
767 *ChemBiochem* 13, 1791–1797. doi:10.1002/cbic.201200208
- 768 Imami, K., Milek, M., Bogdanow, B., Yasuda, T., Kastelic, N., Zauber, H., Ishihama, Y.,
769 Landthaler, M., Selbach, M., 2018. Phosphorylation of the Ribosomal Protein
770 RPL12/uL11 Affects Translation during Mitosis. *Mol. Cell* 72, 84–98.e9.
771 doi:10.1016/j.molcel.2018.08.019
- 772 Jansson, M.D., Damas, N.D., Lees, M., Jacobsen, A., Lund, A.H., 2015. miR-339-5p
773 regulates the p53 tumor-suppressor pathway by targeting MDM2. *Oncogene* 34, 1908–
774 1918. doi:10.1038/onc.2014.130
- 775 Jansson, M.D., Häfner, S.J., Altinel, K., Tehler, D., Krogh, N., Jakobsen, E., Andersen, J.V.,
776 Andersen, K.L., Schoof, E.M., Ménard, P., Nielsen, H., Lund, A.H., 2021. Regulation of
777 translation by site-specific ribosomal RNA methylation. *Nat. Struct. Mol. Biol.* 28, 889–
778 899. doi:10.1038/s41594-021-00669-4
- 779 Kampen, K.R., Sulima, S.O., Vereecke, S., De Keersmaecker, K., 2020. Hallmarks of
780 ribosomopathies. *Nucleic Acids Res.* 48, 1013–1028. doi:10.1093/nar/gkz637
- 781 Kapur, M., Monaghan, C.E., Ackerman, S.L., 2017. Regulation of mRNA Translation in

- 782 Neurons-A Matter of Life and Death. *Neuron* 96, 616–637.
783 doi:10.1016/j.neuron.2017.09.057
- 784 Khajuria, R.K., Munschauer, M., Ulirsch, J.C., Fiorini, C., Ludwig, L.S., McFarland, S.K.,
785 Abdulhay, N.J., Specht, H., Keshishian, H., Mani, D.R., Jovanovic, M., Ellis, S.R.,
786 Fulco, C.P., Engreitz, J.M., Schütz, S., Lian, J., Gripp, K.W., Weinberg, O.K., Pinkus,
787 G.S., Gehrke, L., Regev, A., Lander, E.S., Gazda, H.T., Lee, W.Y., Panse, V.G., Carr,
788 S.A., Sankaran, V.G., 2018. Ribosome Levels Selectively Regulate Translation and
789 Lineage Commitment in Human Hematopoiesis. *Cell* 173, 90–103.e19.
790 doi:10.1016/j.cell.2018.02.036
- 791 Khandjian, E.W., Corbin, F., Woerly, S., Rousseau, F., 1996. The fragile X mental
792 retardation protein is associated with ribosomes. *Nat. Genet.* 12, 91–93.
793 doi:10.1038/ng0196-91
- 794 Khatter, H., Myasnikov, A.G., Natchiar, S.K., Klaholz, B.P., 2015. Structure of the human
795 80S ribosome. *Nature* 520, 640–645. doi:10.1038/nature14427
- 796 Klinge, S., Voigts-Hoffmann, F., Leibundgut, M., Arpagaus, S., Ban, N., 2011. Crystal
797 structure of the eukaryotic 60S ribosomal subunit in complex with initiation factor 6.
798 *Science* 334, 941–948. doi:10.1126/science.1211204
- 799 Kondrashov, N., Pusic, A., Stumpf, C.R., Shimizu, K., Hsieh, A.C., Ishijima, J., Shiroishi, T.,
800 Barna, M., 2011. Ribosome-mediated specificity in Hox mRNA translation and
801 vertebrate tissue patterning. *Cell* 145, 383–397. doi:10.1016/j.cell.2011.03.028
- 802 Kovacs, N.A., Penev, P.I., Venapally, A., Petrov, A.S., Williams, L.D., 2018. Circular
803 Permutation Obscures Universality of a Ribosomal Protein. *J Mol Evol* 86, 581–592.
804 doi:10.1007/s00239-018-9869-1
- 805 Kraushar, M.L., Krupp, F., Harnett, D., Turko, P., Ambrozkiwicz, M.C., Sprink, T., Imami,
806 K., Günnigmann, M., Zinnall, U., Vieira-Vieira, C.H., Schaub, T., Münster-Wandowski,
807 A., Bürger, J., Borisova, E., Yamamoto, H., Rasin, M.-R., Ohler, U., Beule, D., Mielke,
808 T., Tarabykin, V., Landthaler, M., Kramer, G., Vida, I., Selbach, M., Spahn, C.M.T.,
809 2020. Protein Synthesis in the Developing Neocortex at Near-Atomic Resolution Reveals
810 Ebp1-Mediated Neuronal Proteostasis at the 60S Tunnel Exit. *Mol. Cell*.
811 doi:10.1016/j.molcel.2020.11.037
- 812 Kraushar, M.L., Viljetic, B., Wijeratne, H.R.S., Thompson, K., Jiao, X., Pike, J.W.,
813 Medvedeva, V., Groszer, M., Kiledjian, M., Hart, R.P., Rasin, M.-R., 2015. Thalamic
814 WNT3 Secretion Spatiotemporally Regulates the Neocortical Ribosome Signature and
815 mRNA Translation to Specify Neocortical Cell Subtypes. *J. Neurosci.* 35, 10911–10926.
816 doi:10.1523/JNEUROSCI.0601-15.2015
- 817 Krogh, N., Birkedal, U., Nielsen, H., 2017. RiboMeth-seq: Profiling of 2'-O-Me in RNA.
818 *Methods Mol. Biol.* 1562, 189–209. doi:10.1007/978-1-4939-6807-7_13
- 819 Krogh, N., Jansson, M.D., Häfner, S.J., Tehler, D., Birkedal, U., Christensen-Dalsgaard, M.,
820 Lund, A.H., Nielsen, H., 2016. Profiling of 2'-O-Me in human rRNA reveals a subset of
821 fractionally modified positions and provides evidence for ribosome heterogeneity.
822 *Nucleic Acids Res.* 44, 7884–7895. doi:10.1093/nar/gkw482
- 823 Laguesse, S., Creppe, C., Nedialkova, D.D., Prévot, P.-P., Borgs, L., Huysseune, S., Franco,
824 B., Duysens, G., Krusy, N., Lee, G., Thelen, N., Thiry, M., Close, P., Chariot, A.,
825 Malgrange, B., Leidel, S.A., Godin, J.D., Nguyen, L., 2015. A Dynamic Unfolded
826 Protein Response Contributes to the Control of Cortical Neurogenesis. *Dev. Cell* 35,
827 553–567. doi:10.1016/j.devcel.2015.11.005
- 828 Lauria, F., Bernabò, P., Tebaldi, T., Groen, E.J.N., Perenthaler, E., Maniscalco, F., Rossi, A.,
829 Donzel, D., Clamer, M., Marchioretto, M., Omersa, N., Orri, J., Dalla Serra, M.,
830 Anderluh, G., Quattrone, A., Inga, A., Gillingwater, T.H., Viero, G., 2020. SMN-primed
831 ribosomes modulate the translation of transcripts related to spinal muscular atrophy. *Nat.*

- 832 Cell Biol. 22, 1239–1251. doi:10.1038/s41556-020-00577-7
- 833 Li, M., Shin, J., Risgaard, R.D., Parries, M.J., Wang, J., Chasman, D., Liu, S., Roy, S.,
834 Bhattacharyya, A., Zhao, X., 2020. Identification of FMR1-regulated molecular networks
835 in human neurodevelopment. *Genome Res.* 30, 361–374. doi:10.1101/gr.251405.119
- 836 Liang, X.-H., Liu, Q., Fournier, M.J., 2007. rRNA Modifications in an Intersubunit Bridge of
837 the Ribosome Strongly Affect Both Ribosome Biogenesis and Activity. *Mol. Cell* 28,
838 965–977. doi:10.1016/j.molcel.2007.10.012
- 839 Liao, Y., Wang, J., Jaehnig, E.J., Shi, Z., Zhang, B., 2019. WebGestalt 2019: gene set
840 analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res.* 47, W199–W205.
841 doi:10.1093/nar/gkz401
- 842 Lins, É.M., Oliveira, N.C.M., Reis, O., Ferrasa, A., Herai, R., Muotri, A.R., Massirer, K.B.,
843 Bengtson, M.H., 2022. Genome-wide translation control analysis of developing human
844 neurons. *Mol Brain* 15, 55–15. doi:10.1186/s13041-022-00940-9
- 845 Luo, Y., Shan, G., Guo, W., Smrt, R.D., Johnson, E.B., Li, X., Pfeiffer, R.L., Szulwach, K.E.,
846 Duan, R., Barkho, B.Z., Li, W., Liu, C., Jin, P., Zhao, X., 2010. Fragile x mental
847 retardation protein regulates proliferation and differentiation of adult neural
848 stem/progenitor cells. *PLoS Genet* 6, e1000898. doi:10.1371/journal.pgen.1000898
- 849 Magee, J.A., Signer, R.A.J., 2021. Developmental Stage-Specific Changes in Protein
850 Synthesis Differentially Sensitize Hematopoietic Stem Cells and Erythroid Progenitors to
851 Impaired Ribosome Biogenesis. *Stem Cell Reports* 16, 20–28.
852 doi:10.1016/j.stemcr.2020.11.017
- 853 Marcel, V., Kielbassa, J., Marchand, V., Natchiar, K.S., Paraqindes, H., Nguyen Van Long,
854 F., Ayadi, L., Bourguignon-Igel, V., Monaco, Lo, P., Monchiet, D., Scott, V., Tonon, L.,
855 Bray, S.E., Diot, A., Jordan, L.B., Thompson, A.M., Bourdon, J.-C., Dubois, T., André,
856 F., Catez, F., Puisieux, A., Motorin, Y., Klaholz, B.P., Viari, A., Diaz, J.-J., 2020.
857 Ribosomal RNA 2'-O-methylation as a novel layer of inter-tumour heterogeneity in breast
858 cancer. *NAR Cancer* 2, 318. doi:10.1093/narcan/zcaa036
- 859 McMahon, M., Contreras, A., Holm, M., Uechi, T., Forester, C.M., Pang, X., Jackson, C.,
860 Calvert, M.E., Chen, B., Quigley, D.A., Luk, J.M., Kelley, R.K., Gordan, J.D., Gill,
861 R.M., Blanchard, S.C., Ruggero, D., 2019. A single H/ACA small nucleolar RNA
862 mediates tumor suppression downstream of oncogenic RAS. *eLife Sciences* 8, E8603.
863 doi:10.7554/eLife.48847
- 864 Mills, E.W., Green, R., 2017. Ribosomopathies: There's strength in numbers. *Science* 358,
865 ean2755. doi:10.1126/science.aan2755
- 866 Mohammed, H., Hernando-Herraez, I., Savino, A., Scialdone, A., Macaulay, I., Mulas, C.,
867 Chandra, T., Voet, T., Dean, W., Nichols, J., Marioni, J.C., Reik, W., 2017. Single-Cell
868 Landscape of Transcriptional Heterogeneity and Cell Fate Decisions during Mouse Early
869 Gastrulation. *Cell Rep* 20, 1215–1228. doi:10.1016/j.celrep.2017.07.009
- 870 Mulligan, K.A., Cheyette, B.N.R., 2012. Wnt Signaling in Vertebrate Neural Development
871 and Function. *J Neuroimmune Pharmacol* 7, 774–787. doi:10.1007/s11481-012-9404-x
- 872 Nachmani, D., Bothmer, A.H., Grisendi, S., Mele, A., Bothmer, D., Lee, J.D., Monteleone,
873 E., Cheng, K., Zhang, Y., Bester, A.C., Guzzetti, A., Mitchell, C.A., Mendez, L.M.,
874 Pozdnyakova, O., Sportoletti, P., Martelli, M.-P., Vulliamy, T.J., Safra, M., Schwartz, S.,
875 Luzzatto, L., Bluteau, O., Soulier, J., Darnell, R.B., Falini, B., Dokal, I., Ito, K.,
876 Clohessy, J.G., Pandolfi, P.P., 2019. Germline NPM1 mutations lead to altered rRNA 2'-
877 O-methylation and cause dyskeratosis congenita. *Nat. Genet.* 174, 1–12.
878 doi:10.1038/s41588-019-0502-z
- 879 Norris, K., Hopes, T., Aspden, J.L., 2021. Ribosome heterogeneity and specialization in
880 development. *Wiley Interdiscip Rev RNA* 12, e1644. doi:10.1002/wrna.1644
- 881 Otero, J.J., Fu, W., Kan, L., Cuadra, A.E., Kessler, J.A., 2004. Beta-catenin signaling is

- 882 required for neural differentiation of embryonic stem cells. *Development* 131, 3545–
883 3557. doi:10.1242/dev.01218
- 884 Pankratz, M.T., Li, X.-J., LaVaute, T.M., Lyons, E.A., Chen, X., Zhang, S.-C., 2007.
885 Directed neural differentiation of human embryonic stem cells via an obligated primitive
886 anterior stage. *Stem Cells* 25, 1511–1520. doi:10.1634/stemcells.2006-0707
- 887 Parks, M.M., Kurylo, C.M., Dass, R.A., Bojmar, L., Lyden, D., Vincent, C.T., Blanchard,
888 S.C., 2018. Variant ribosomal RNA alleles are conserved and exhibit tissue-specific
889 expression. *Sci Adv.* doi:10.1126/sciadv.aao0665
- 890 Polikanov, Y.S., Melnikov, S.V., Söll, D., Steitz, T.A., 2015. Structural insights into the role
891 of rRNA modifications in protein synthesis and ribosome assembly. *Nat. Struct. Mol.*
892 *Biol.* 22, 342–344. doi:10.1038/nsmb.2992
- 893 Ramachandran, S., Krogh, N., Jørgensen, T.E., Johansen, S.D., Nielsen, H., Babiak, I., 2020.
894 The shift from early to late types of ribosomes in zebrafish development involves
895 changes at a subset of rRNA 2'-O-Me sites. *RNA* 26, 1919–1934.
896 doi:10.1261/rna.076760.120
- 897 Ramakrishnan, V., 2002. Ribosome structure and the mechanism of translation. *Cell* 108,
898 557–572. doi:10.1016/s0092-8674(02)00619-0
- 899 Rappsilber, J., Mann, M., Ishihama, Y., 2007. Protocol for micro-purification, enrichment,
900 pre-fractionation and storage of peptides for proteomics using StageTips. *Nature*
901 *Protocols* 2, 1896–1906. doi:10.1038/nprot.2007.261
- 902 Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics
903 of Mammalian Proteomes, 2011. Ribosome Profiling of Mouse Embryonic Stem Cells
904 Reveals the Complexity and Dynamics of Mammalian Proteomes. *Cell* 147, 789–802.
905 doi:10.1016/j.cell.2011.10.002
- 906 Richter, J.D., Zhao, X., 2021. The molecular biology of FMRP: new insights into fragile X
907 syndrome. *Nature Reviews Neuroscience* 22, 209–222. doi:10.1038/s41583-021-00432-0
- 908 Rifes, P., Isaksson, M., Rathore, G.S., Aldrin-Kirk, P., Møller, O.K., Barzaghi, G., Lee, J.,
909 Egerod, K.L., Rausch, D.M., Parmar, M., Pers, T.H., Laurell, T., Kirkeby, A., 2020.
910 Modeling neural tube development by differentiation of human embryonic stem cells in a
911 microfluidic WNT gradient. *Nature Biotechnology* 2018 36:3 5, 525–9.
912 doi:10.1038/s41587-020-0525-0
- 913 Santoro, M.R., Bray, S.M., Warren, S.T., 2012. Molecular mechanisms of fragile X
914 syndrome: a twenty-year perspective. *Annu Rev Pathol* 7, 219–245.
915 doi:10.1146/annurev-pathol-011811-132457
- 916 Shi, Z., Barna, M., 2015. Translating the genome in time and space: specialized ribosomes,
917 RNA regulons, and RNA-binding proteins. *Annu. Rev. Cell Dev. Biol.* 31, 31–54.
918 doi:10.1146/annurev-cellbio-100814-125346
- 919 Shi, Z., Fujii, K., Kovary, K.M., Genuth, N.R., R st, H.L., Teruel, M.N., Barna, M., 2017.
920 Heterogeneous Ribosomes Preferentially Translate Distinct Subpools of mRNAs
921 Genome-wide. *Mol. Cell.* doi:10.1016/j.molcel.2017.05.021
- 922 Shimojo, D., Onodera, K., Doi-Torii, Y., Ishihara, Y., Hattori, C., Miwa, Y., Tanaka, S.,
923 Okada, R., Ohyama, M., Shoji, M., Nakanishi, A., Doyu, M., Okano, H., Okada, Y.,
924 2015. Rapid, efficient, and simple motor neuron differentiation from human pluripotent
925 stem cells. *Mol Brain* 8, 79–15. doi:10.1186/s13041-015-0172-4
- 926 Sierra, R.A., Hoverter, N.P., Ramirez, R.N., Vuong, L.M., Mortazavi, A., Merrill, B.J.,
927 Waterman, M.L., Donovan, P.J., 2018. TCF7L1 suppresses primitive streak gene
928 expression to support human embryonic stem cell pluripotency. *Development* 145,
929 dev161075. doi:10.1242/dev.161075
- 930 Slavov, N., Semrau, S., Airoidi, E., Budnik, B., van Oudenaarden, A., 2015. Differential
931 Stoichiometry among Core Ribosomal Proteins. *Cell Rep* 13, 865–873.

- 932 doi:10.1016/j.celrep.2015.09.056
933 Sloan, K.E., Warda, A.S., Sharma, S., Entian, K.-D., Lafontaine, D.L.J., Bohnsack, M.T.,
934 2016. Tuning the ribosome: The influence of rRNA modification on eukaryotic ribosome
935 biogenesis and function. *RNA Biol* 14, 1138–1152. doi:10.1080/15476286.2016.1259781
936 Steitz, J.A., Tycowski, K.T., 1995. Small RNA chaperones for ribosome biogenesis. *Science*
937 270, 1626–1627. doi:10.1126/science.270.5242.1626
938 Sternberg, S.H., Fei, J., Prywes, N., McGrath, K.A., Gonzalez, R.L., 2009. Translation
939 factors direct intrinsic ribosome dynamics during translation termination and ribosome
940 recycling. *Nat. Struct. Mol. Biol.* 16, 861–868. doi:10.1038/nsmb.1622
941 Sturgeon, C.M., Ditadi, A., Awong, G., Kennedy, M., Keller, G., 2014. Wnt signaling
942 controls the specification of definitive and primitive hematopoiesis from human
943 pluripotent stem cells. *Nature Biotechnology* 2018 36:3 32, 554–561.
944 doi:10.1038/nbt.2915
945 Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S.,
946 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors.
947 *Cell* 131, 861–872. doi:10.1016/j.cell.2007.11.019
948 Translational control through ribosome heterogeneity and functional specialization, 2022.
949 Translational control through ribosome heterogeneity and functional specialization.
950 *Trends Biochem. Sci.* 47, 66–81. doi:10.1016/j.tibs.2021.07.001
951 Translational control through ribosome heterogeneity and functional specialization, 2021.
952 Translational control through ribosome heterogeneity and functional specialization.
953 *Trends Biochem. Sci.* doi:10.1016/j.tibs.2021.07.001
954 Uechi, T., Maeda, N., Tanaka, T., Kenmochi, N., 2002. Functional second genes generated
955 by retrotransposition of the X-linked ribosomal protein genes. *Nucleic Acids Res.* 30,
956 5369–5375. doi:10.1093/nar/gkf696
957 Wang, R., Amoyel, M., 2022. mRNA Translation Is Dynamically Regulated to Instruct Stem
958 Cell Fate. *Front Mol Biosci* 9, 863885. doi:10.3389/fmolb.2022.863885
959 Wang, Y.-C., Peterson, S.E., Loring, J.F., 2014. Protein post-translational modifications and
960 regulation of pluripotency in human stem cells. *Cell Res.* 24, 143–160.
961 doi:10.1038/cr.2013.151
962 Xue, S., Barna, M., 2012. Specialized ribosomes: a new frontier in gene regulation and
963 organismal biology. *Nature Reviews Molecular Cell Biology* 13, 355–369.
964 doi:10.1038/nrm3359
965 Yamada, S.B., Gendron, T.F., Niccoli, T., Genuth, N.R., Grosely, R., Shi, Y., Glaria, I.,
966 Kramer, N.J., Nakayama, L., Fang, S., Dinger, T.J.I., Thoeng, A., Rocha, G., Barna, M.,
967 Puglisi, J.D., Partridge, L., Ichida, J.K., Isaacs, A.M., Petrucelli, L., Gitler, A.D., 2019.
968 RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative
969 disease-associated nucleotide repeats. *Nat. Neurosci.* 22, 1383–1388.
970 doi:10.1038/s41593-019-0455-7
971 Zhao, B.S., Roundtree, I.A., He, C., 2017. Post-transcriptional gene regulation by mRNA
972 modifications. *Nature Reviews Molecular Cell Biology* 18, 31–42.
973 doi:10.1038/nrm.2016.132

976 **Figure Legends**

977

978 **Main Figures**

979

980 **Figure 1: rRNA 2'-O-me dynamics in the developing mouse brain.**

981

982 A: Murine model system. Cortex (red) was obtained by dissection from 7 developmental stages
983 ranging from E11 to adult. Hippocampus (green), olfactory bulb (yellow), and cerebellum
984 (blue) were taken from neonates (P0) and adult.

985

986 B: Heat-map depicting rRNA 2'-O-me levels in the developing mouse cortex and a mouse
987 embryonic stem cell line measured by RiboMeth-seq. Columns represent developmental
988 stages, rows all rRNA positions known to be potentially 2'-O-methylated from the 28S, 18S,
989 and 5.8S rRNA. The color scale (from blue for low, to red for high) indicates the average RMS
990 score from three biological replicates.

991

992 C: RMS scores for two examples of rRNA positions displaying 2'-O-me dynamics during
993 mouse cortex development, position 18S:U354 on the small subunit, and 28S:G4593 on the
994 large subunit. Standard deviations refer to biological triplicates. ns: not significant. *: $P \leq 0.05$,
995 **: $P \leq 0.01$, ***: $P \leq 0.001$, ****: $P \leq 0.0001$ (Welch's unpaired t-test).

996

997 D: Comparison of rRNA 2'-O-me levels measured by RiboMeth-seq between four brain regions
998 (cortex CTX, hippocampus HPC, olfactory bulb OFB, cerebellum CBM) from adult mice.
999 Known methylated positions from the 28S, 18S, and 5.8S rRNA are depicted on separate
1000 graphs on the X-axis. The Y-axis corresponds to the average RMS score. Points represent mean
1001 RMS scores of $n = 3$ sequenced libraries from different animals. Error bars represent \pm s.d.

1002

1003 E: 2'-O-me levels at rRNA position 18S:G436 in different brain regions at the adult stage.
1004 Error bars represent \pm s.d. of biological triplicates (points). ns: not significant. *: $P \leq 0.05$, **: $P \leq 0.01$,
1005 ***: $P \leq 0.001$, ****: $P \leq 0.0001$ (Welch's unpaired t-test).

1006

1007 F: As (D), for hippocampus of neonates (P0) (black) and adult mice (green).

1008

1009 **Figure 2: 2'-O-me dynamics during directed differentiation of human ES cells.**

1010

1011 A: Human model system. Human embryonic stem cells (hESCs), H9 and HUES4, as well as
1012 human induced pluripotent stem cells (hiPSCs), KOLF2, were differentiated *in vitro* into the 3
1013 embryonic germ layers endo-, meso-, and ectoderm. Neural differentiation represents ectoderm
1014 differentiation, subdivided into intermediate stages of cellular commitment, including early
1015 neural progenitor cells (eNPCs), late neural precursors (INPCs), and mature neurons (MNs).
1016 The approximate time to reach the desired differentiation state is indicated.

1017

1018 B: Heat-map showing RMS scores for H9^{WT} cells at the pluripotent stage (hESCs) and
1019 differentiated into endoderm, mesoderm, and ectoderm, respectively (columns). Ectoderm is
1020 further divided into early neural progenitor cells (eNPCs), late neural progenitor cells (INPCs),
1021 and mature neurons (MNs). Rows correspond to all rRNA positions known to be potentially
1022 methylated from the 28S, 18S, and 5.8S rRNA. Methylation levels range from absent (RMS
1023 score = 0, blue) to full (RMS score = 1, red).

1024

1025 C: Different types of rRNA 2'-O-me dynamics during H9^{WT} differentiation into the 3 embryonic
1026 germ layers measured by RiboMeth-Seq. Cell stages are indicated on the X-axis, the Y-axis
1027 represents the fraction of rRNA molecules carrying a methylation at a certain position in these
1028 samples (RMS score). Standard deviations refer to biological triplicates.

1029

1030 D: rRNA 2'-O-me dynamics at the large subunit position 28S:U3904 upon H9^{WT}
1031 differentiation into the three embryonic germ layers measured by Ribometh-Seq on biological
1032 triplicates. ns: not significant. *: $P \leq 0.05$, **: $P \leq 0.01$, ***: $P \leq 0.001$, ****: $P \leq 0.0001$ (Welch's
1033 unpaired t-test).

1034

1035 E: Left: localization of 28S:U3904 in the 3D structure of human rRNA. Blue: large subunit
1036 (28S). Yellow: small subunit (18S). Orange: tRNA. Red: 28S:U3904. Right, top: close-up of
1037 the human ribosome region harboring 28S:U3904, color code as (left). Right, bottom: 3D
1038 configuration of 2'-O-methylated 28S:U3904 (yellow), the CCA-portion of the E-tRNA
1039 (green/orange) and the conserved PLTQGG motif of ribosomal protein RPL36A(L)
1040 (cyan/grey).

1041

1042 F: SNORD52 expression during the first week of neural induction of H9^{WT}, assayed by RT-
1043 qPCR. Normalized to the housekeeping gene SNORD46. Error bars represent \pm s.d.
1044

1045 **Figure 3: Loss of 2'-O-me at 28S:U3904 shifts cell identity from ESCs to NPCs under ES**
1046 **conditions and biases differentiation potential towards neurogenesis.**

1047

1048 A: Representative bright-field images of H9^{WT} ESCs (WT), CRISPR control H9^{CTRL} (CTRL),
1049 and two SNORD52 knock-out (H9^{52KO}) clones (KO1, KO2) under hESC culture conditions.
1050 Magnification: 20x. White arrows indicate neuritic outgrowths. Representative images from
1051 n=3 experiments are shown.

1052

1053 B: Immunofluorescence staining of H9^{WT}, H9^{CTRL}, and H9^{52KO} clones for the pluripotency
1054 transcription factor OCT4 (green) and the neurogenesis transcription factor PAX6 (red). The
1055 cells were grown under hESC culture conditions. Magnification 20x. Representative images
1056 from n=3 experiments are shown.

1057

1058 C: Heat-map showing RT-qPCR assay of markers for pluripotency and differentiation into the
1059 3 germ layers (rows) applied to H9^{WT}, H9^{CTRL}, and two H9^{52KO} clones as biological triplicates
1060 (columns) under hESC conditions (day 0), and at day 7 of ectoderm differentiation. Color scale
1061 indicates expression levels, from blue (low) to red (high). Values are normalized to GAPDH
1062 and to their respective expression ranges over the differentiation time-course.

1063

1064 D: Bright-field and immunofluorescence images of H9^{WT}, H9^{CTRL}, and H9^{52KO} cells at day 7
1065 of neural induction. Magnification 10x. Blue: DAPI. Red: ZO1, for visualization of neural
1066 rosette structures. Representative images from n=4 experiments are shown.

1067

1068 E: Immunofluorescence staining at day 5 of neural differentiation of H9^{WT}, H9^{CTRL}, and two
1069 H9^{52KO} clones using nuclear staining (DAPI, blue) and an antibody against neuron-specific
1070 TUJ1 (β -tubulin III, green). Magnification: 20x. Representative images from n=3 experiments
1071 are shown.

1072

1073

1074

1075

1076

1077

1078

1079 **Figure 4: Manipulation of 28S:U3904 2'-O-me levels modifies the long-term neural**
1080 **differentiation potential of hESCs.**

1081

1082 A: Representative (of n=4) bright field images of H9^{WT}, H9^{52KO}, and H9^{52OE} cells at day 21 of
1083 neural maturation. Magnification: 20x.

1084

1085 B: Heat-map based on RT-qPCR data for regional brain markers in H9^{WT}, H9^{52KO}, and H9^{52OE}
1086 cells at days 3 and 7 of early neural induction and after seven weeks of neural maturation.

1087 Genes are grouped by brain region. Values are normalized to GAPDH and reference values for
1088 a H9^{WT} cell line (also normalized to GAPDH), then transformed by log2.

1089 Color scale indicates expression levels, from blue (low) to red (high).

1090

1091 C: Representative immunofluorescence images (of n=3) showing staining of H9^{WT} and H9^{52KO}
1092 cells after three weeks of neural maturation. Magnification: 20x. Blue: DAPI, green: MAP2,
1093 red: OTX2, yellow: TTR.

1094

1095 D: Long-term differentiation potential of H9^{WT}, H9^{52KO}, and H9^{52OE} cells in terms of anterior-
1096 posterior brain regions.

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109 **Figure 5: WNT pathway translation is repressed by 28S:U3904 methylation.**

1110

1111 A: Changes in mRNA expression and ribosome footprint levels from ribosome profiling data,
1112 comparing H9^{WT} and H9^{52KO} cells (n=3 libraries from individual cultures). Scatter plot (left)
1113 with mRNA transcripts colored to indicated regulation type. Number of sequenced transcripts
1114 analyzed given by *n*. Numbers of transcripts up- or down-regulated in H9^{52KO} relative to H9
1115 WT cells in the translation alone set also shown (TL-UP, TL-DN, respectively). Histogram
1116 (right) giving the number of mRNA transcripts significantly regulated in each category
1117 (Benjamini–Hochberg *P*_{adj} < 0.05).

1118

1119 B: Gene ontology analysis of mRNA transcripts in TL-UP set. Biological process GO
1120 categories with FDR < 0.05 are labeled. Number of genes overlapping with each GO category
1121 indicated by the color-scale gradient.

1122

1123 C: WNT activity measured by a TOP/FOP reporter assay in H9^{WT} and H9^{52KO} cells. Luciferase
1124 activity is used as readout for WNT activity and normalized to Renilla activity from a
1125 transfection control plasmid. The TOP plasmid contains WNT response elements, the FOP
1126 plasmid mutated versions of the latter. ns: not significant. *: P≤0.05, **: P≤0.01, ***:P≤0.001,
1127 ****:P≤0.0001 (Welch's unpaired t-test).

1128

1129 D: The same TOP/FOP reporter assay as in C with H9^{WT} and two H9^{52OE} clones over the course
1130 of the first seven days of neural induction. Average of three independent experiments. ns: not
1131 significant. *: P≤0.05, **: P≤0.01, ***:P≤0.001, ****:P≤0.0001 (Welch's unpaired t-test).

1132

1133 E: Immunofluorescence images of H9^{WT}, H9^{52KO}, and H9^{52OE} cells for beta-catenin (green) and
1134 nuclear staining (DAPI, blue). Top row magnification: 20x. Bottom row magnification: 40x.
1135 Representative images from n=3 biological replicates.

1136

1137 F: Quantification of the subcellular localization of beta-catenin in H9^{WT}, H9^{52KO}, and early
1138 neural progenitors derived from H9^{WT} (H9^{NPC}). ns: not significant. *: P≤0.05, **: P≤0.01,
1139 ***:P≤0.001, ****:P≤0.0001 (Welch's unpaired t-test).

1140

1141 G: Western Blot for RECK (left) and CITED1 (right) in H9^{WT} and H9^{52KO} cells under hESC
1142 conditions.
1143

1144 **Figure 6: FMRP preferentially binds ribosomes lacking 28S:U3904 methylation**

1145

1146 A: Protein abundance changes in H9^{52KO} (52KO) compared to H9^{WT} (WT) ribosome associated
1147 proteins in monosomes (left) and polysomes (right). Log 2 fold change in abundance
1148 (52KO/WT) and $-\log_{10}$ (P values) shown ($n = 3$ independent protein samples per condition).
1149 Those significantly changing (Benjamini–Hochberg $P_{adj} < 0.05$) are colored (magenta). n
1150 denotes number of proteins analyzed. Numbers of proteins enriched in either sample is
1151 indicated (Enr WT, Enr 52KO). FMRP is highlighted in red.

1152

1153 B: Protein abundance changes in H9^{52KO} (52KO) compared to H9^{NPC} (NPC) ribosome
1154 associated proteins in monosomes (left) and polysomes (right). \log_2 (abundance ratios)
1155 (52KO/WT) and $-\log_{10}$ (P values) shown ($n = 3$ independent protein samples per condition).
1156 Those significantly changing (Benjamini–Hochberg $P_{adj} < 0.05$) are colored (magenta). n
1157 denotes number of proteins analyzed. Numbers of proteins enriched in either sample is
1158 indicated (Enr WT, Enr 52KO). FMRP is highlighted in red.

1159

1160 C: Protein abundance changes in H9^{NPC} (NPC) compared to H9^{WT} (WT) ribosome associated
1161 proteins in monosomes (left) and polysomes (right). \log_2 (abundance ratios) (NPC/WT) and
1162 $-\log_{10}$ (P values) shown ($n = 3$ independent protein samples per condition). Those
1163 significantly changing (Benjamini–Hochberg $P_{adj} < 0.05$) are colored (magenta). n denotes
1164 number of proteins analyzed. Numbers of proteins enriched in either sample is indicated (Enr
1165 NPC, Enr WT). FMRP is highlighted in red.

1166

1167 D: Detection of total cellular and ribosome-bound FMRP protein by Western Blot in H9^{WT}
1168 (WT), H9^{52KO} (KO), H9^{52OE} (OE), H9^{NPC} (NPC WT), and H9^{52OE}-derived (NPC OE) cells. IP
1169 (input) = whole cell lysate, RC (ribosome cushion) = ribosomes purified by sucrose cushion.
1170 Vinculin serves as a control for appropriate separation of input and purified ribosomes, RPL4
1171 and RPS18 for normalization to ribosome abundance.

1172

1173 E: Quantification of the enrichment of FMRP in the ribosome-bound fraction based on (C).
1174 Bands were quantified, then subsequently the values for FMRP normalized to the
1175 corresponding ribosomal protein (RPL4 or RPS18), and finally the ratio of the ribosome-bound

1176 fraction over the input fraction calculated. See Supplementary Figure 9 for three more
1177 experimental repeats.

1178

1179 F: 3D model of FMRP localization in the imminent vicinity of 28S:U3904, based on cryoEM
1180 data from drosophila. FMRP (red) is in direct contact with the E-site tRNA (orange) and the
1181 ribosomal protein RPL36A(L) (grey), which in turn lies within contact distance of 28S:U3904
1182 (yellow, 28S rRNA in blue). The binding position of cycloheximide (CHX, violet) is
1183 additionally shown.

1184

1185 **Supplementary Figures**

1186

1187 **Supplementary Figure 1: Additional RMS analyses of adult and neonate mouse brain**
1188 **regions**

1189

1190 A: Comparison of rRNA 2'-O-me levels measured by RiboMeth-seq between four brain regions
1191 (cortex CTX, hippocampus HPC, olfactory bulb OFB, cerebellum CBM) from neonate mice
1192 (P0). Known methylated positions from the 28S, 18S, and 5.8S rRNA are depicted on separate
1193 graphs on the X-axis. The Y-axis corresponds to the average RMS score. Points represent mean
1194 RMS scores of $n = 3$ sequenced libraries from different animals. Error bars represent \pm s.d.

1195

1196 B: PCA analysis of RMS data from four adult mouse brain regions: cerebellum (CBM), cortex
1197 (CTX), hippocampus (HPC), and olfactory bulb (OFB). 3 libraries (biological replicates) per
1198 brain region.

1199

1200 C: Pairwise comparison of rRNA 2'-O-me levels between adult and neonates (P0) for cortex
1201 (CTX), olfactory bulb (OFB), and cerebellum (CBM). RiboMeth-seq (RMS) scores
1202 representing fraction of 2'-O-methylation at each potentially methylated site in 18S, 28S, and
1203 5.8S rRNAs present in total RNA purified from the indicated brain regions. Nucleotide
1204 positions in respective rRNAs are indicated. Points represent mean RMS scores of $n = 3$
1205 sequenced libraries from different animals. Error bars represent \pm s.d

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218 **Supplementary Figure 2: Confirmation of efficient directed *in vitro* differentiation of**
1219 **hESCs into the three embryonic germ layers**

1220

1221 A: Heat-map based on RT-qPCR data confirming expression of known marker genes (rows)
1222 for pluripotent H9^{WT} hESCs and their differentiated progeny (columns) on the final day of
1223 differentiation (day 7 for ectoderm, day 5 for endoderm and mesoderm). Three independent
1224 experiments are plotted as separate columns per differentiation type. Blue corresponds to low
1225 expression levels, red to high levels. The genes are grouped by cell type (stem cells or germ
1226 layer). Values are normalized to GAPDH and to their respective expression ranges over the
1227 differentiation time-course.

1228

1229 B: Time-course of mRNA expression normalized to GAPDH for representative marker genes
1230 during differentiation of H9^{WT} hESCs into the three germ layers measured by RT-qPCR.
1231 OCT4: pluripotency marker, PAX6: ectoderm marker, CER1: endoderm marker, T/Brachyury:
1232 mesoderm marker. Error bars indicate \pm SD of n=3 biological replicates.

1233

1234 C: Immunofluorescence staining for pluripotency and appropriate differentiation into the three
1235 germ layers in H9^{WT}. Blue: DAPI. Green: germ line-specific differentiation markers.

1236 OCT 4 (pluripotency) under hESCs culture conditions, SOX17 at day 6 of endoderm
1237 differentiation, T/BRACHYURY at day 3 of mesoderm differentiation, and NESTIN at day 7
1238 of ectoderm differentiation. Magnification: 20x. Representative images from n=3 experiments
1239 are shown.

1240

1241 D: Comparison of the differentiation potential into the three embryonic germ layers of different
1242 pluripotent cell lines (H9, HUES4, and Kolf2 iPS cells) by RT-qPCR. Values are normalized
1243 to GAPDH. Error bars indicate \pm SD from n=3 independent experiments.

1244

1245

1246

1247

1248

1249

1250

1251

1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285

Supplementary Figure 3: Differentiation-related rRNA 2'-O-me dynamics are reproducible between different pluripotent cell lines.

A: Two by two correlation between cell lines (H9, HUES4, Kolf2 iPS) for RMS values at the pluripotent stage or after differentiation into endoderm and mesoderm for all known rRNA positions to be potentially 2'-O-methylated. Small subunit (18S) and large subunit (28S) positions are plotted in separate graphs. Error bars indicate \pm SD from n=3 independent experiments.

1286 **Supplementary Figure 4: Characteristics of the SNORD52 locus and generation of**
1287 **SNORD52 knock-out clones by CRISPR/Cas9.**

1288

1289 A: Genomic locus of SNORD52, SNORD48, and their host gene SNHG32. e0-e5: SNHG32
1290 exons. se3: short exon 3. le4: long exon 4. HSPA1B: Heat Shock Protein Family A Member
1291 1B gene.

1292

1293 B: Localization of 28S:U3904 (guided by SNORD52) and 28S:C1868 (guided by SNORD48)
1294 in the human rRNA 3D structure (PyMol graphic). Large subunit (28S) in green, small subunit
1295 (18S) in blue, 5.8S in turquoise, tRNA in magenta and methylation sites in red.

1296

1297 C: Respective rRNA 2'-O-me dynamics of 28S:C1868 and 28S:U3904 during the
1298 differentiation into the three embryonic germ layers. Error bars indicate \pm SD from n=3
1299 independent experiments.

1300

1301 D: RNAseq tracks for the SNHG32 gene in H9^{WT} (H9 WT) and H9^{52KO} (SNORD52 KO) cells
1302 under hESC culture conditions.

1303

1304 E: Sequence of SNORD52 preceding exon 4 of SNHG32, as well as the location and sequence
1305 of the CRISPR/Cas9 guides used to excise SNORD52 to generate the H9^{52KO} clones.

1306

1307 F: PCR products for the region spanning the SNORD52 genomic region run on agarose gel to
1308 confirm the deletion of SNORD52 in the two KO clones. Control (H9^{CTRL}) clones have
1309 undergone transfection with the CRISPR/Cas9 guides, but no deletion has taken place and the
1310 SNORD52 locus is intact.

1311

1312 G: Confirmation by RT-qPCR of the absence of SNORD52 expression in the two H9^{52KO}
1313 clones compared to H9^{WT} cells. Values were normalized to GAPDH. Error bars indicate \pm SD
1314 of n=3 technical triplicates.

1315

1316 H: Deletion of SNORD52 fully removes 2'-O-methylation at 28S:U3904. RMS values for all
1317 known 2'-O-me positions at the large subunit (28S) compared between H9^{WT} and the two
1318 H9^{52KO} clones. 28S:U3904 is highlighted in red. Error bars indicate \pm SD of n=3 sequenced
1319 libraries from individual cell cultures.

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329

1330

1331

1332

1333

1334 **Supplementary Figure 5: SNORD52 deletion correlates with failure to up-regulate**
1335 **certain neural markers and impedes differentiation into endoderm and mesoderm.**

1336

1337 A: Proliferation assay by crystal violet for H9^{WT}, H9^{52KO} clones, and H9^{WT}-derived neural
1338 progenitor cells (H9^{NPC}). Error bars indicate \pm SD of n=3 replicates.

1339

1340 B: Immunofluorescence staining for ectoderm markers NESTIN and MAP2 in H9^{WT} and
1341 H9^{52KO} cells at day 2 (left) and 5 (right) of neural induction. Blue: DAPI. Green: NESTIN or
1342 MAP2. Magnification: 20x. Representative images from n=3 experiments are shown.

1343

1344 C: Time-course of ectoderm marker gene (*PAX6*, *OTX2*, *LHX2*, *SOX10*) expression normalized
1345 to GAPDH during neural induction on H9^{WT} (WT), H9^{CTRL} (CTRL), and H9^{52KO} clones (KO1
1346 and KO2) cells by RT-qCPR. Error bars indicate \pm SD of n=3 biological replicates.

1347

1348 D: Bright-field microscopy images of H9^{WT}, H9^{CTRL}, and H9^{52KO} cultures at day 5 of endoderm
1349 (left) and mesoderm (right) differentiation. Magnification: 10x. Representative images from
1350 n=3 experiments are shown.

1351

1352 E: Heat-map based on RT-qPCR data for pluripotency and differentiation markers (columns)
1353 for H9^{WT}, H9^{CTRL}, and H9^{52KO} cells at day 5 of endoderm (left) or mesoderm (right)
1354 differentiation. Three independent experiments are plotted as separate columns per
1355 differentiation type. Values are normalized to GAPDH and subsequently to the range of all
1356 values per primer pair throughout the entire differentiation time-course (day 0 – day 5). Blue
1357 corresponds to low expression levels, red to high levels. The genes are grouped by cell type
1358 (stem cells or germ layer).

1359

1360 F: Time-course of endoderm marker *CER1* and mesoderm marker *T/Brachyury* mRNA
1361 expression normalized to GAPDH during the differentiation of H9^{WT}, H9^{CTRL}, and H9^{52KO} cells
1362 into endoderm and mesoderm respectively assayed by RT-qPCR. Error bars indicate \pm SD of
1363 n=3 biological replicates.

1364

1365 G: SNORD52 was re-inserted into H9^{52KO} cells by targeting the AAVS1 locus with a 2-exon
1366 EGFP construct harboring SNORD52 in its intron. Cells did not revert to the ESC stage but
1367 differentiated terminally into neural-like cells while expressing high levels of the EGFP-

1368 SNORD52 construct. Two representative clones are shown. Top: bright-field. Bottom: EGFP.

1369 Magnification: 40x.

1370

1371

1372

1373

1374

1375

1376

1377

1378

1379

1380

1381

1382

1383 **Supplementary Figure 6: Generation and characterization of SNORD52 constitutive**
1384 **overexpression cell lines.**

1385

1386 A: Fluorescence images of two H9-derived cell lines with constitutive SNORD52
1387 overexpression (H9^{52OE}, OE1 and OE2) by targeting the AAVS1 locus with a 2-exon EGFP
1388 construct harboring SNORD52 in the intron. Top panels show EGFP, bottom panels EGFP and
1389 DAPI. Blue: DAPI. Green: EGFP. Magnification: 20x.

1390

1391 B: Fluorescence images of H9^{52OE} cells following differentiation. H9^{52OE}-derived early neural
1392 progenitor cells (H9^{52OE-eNPC}) are shown. Top panels show EGFP, bottom panels EGFP and
1393 DAPI. Blue: DAPI. Green: EGFP. Magnification: 20x.

1394

1395 C: Constitutive expression of the EGFP-SNORD52 construct achieves overexpression of
1396 SNORD52 throughout ectoderm differentiation. RT-qPCR data from neural induction in H9^{WT}
1397 (WT) and H9^{52OE} cell lines (OE1 and OE2). Normalization to SNORD46. Error bars indicate
1398 \pm SD of n=3 technical triplicates.

1399

1400 D: 2'-O-me at LSU 3904 in H9^{52OE} cells (OE1 and OE2) under hESC culture conditions.
1401 RMS scores shown. Error bars indicate \pm SD of n=3 sequenced libraries from individual cell
1402 cultures.

1403

1404 E: Pluripotency (*OCT4*) and germ-layer specific marker gene expression (*PAX6*, *FOXA2*,
1405 *CXCR4*) during differentiation in H9^{WT} (WT) and H9^{52OE} cells (OE1 and OE2), measured by
1406 RT-qPCR normalized to GAPDH. Error bars indicate \pm SD of n=3 technical replicates.

1407

1408 F: Representative fluorescence images of staining for ZO1 (red) and DAPI (blue) in order to
1409 highlight neural rosette structures at day 7 of ectoderm differentiation in H9^{WT} and H9^{52OE} cells.

1410

1411 G: Expression of *OTX2* over neural induction in H9^{WT} (WT) and H9^{52OE} (OE1 and OE2) cells
1412 measured by RT-qPCR. Values normalized to GAPDH. Error bars indicate \pm SD of n=3
1413 independent experiments.

1414

1415 **Supplementary Figure 7: Analysis of ribosome biogenesis, global translation, and**
1416 **polysome profiles in cells lacking 28S:3904-me**

1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448

A: Analysis of rRNA biogenesis pathways in H9^{WT} (WT), H9^{52KO} (SNORD52 KO) cells, and H9^{NPC} (NPC). Left: schematic showing rRNA processing steps and location of probes ‘a’ and ‘b’. Right: levels of pre-rRNA, processing intermediates, and mature 18S and 28S rRNA as assessed by northern blot.

B: Nascent peptide synthesis assessed by OPP incorporation assay in H9^{WT} (WT), H9^{WT} with an EGFP-only transgene (WT-EGFP), H9^{52KO} (KO1 and KO2) cells, H9^{NPC} (NPC-WT), WT-EGFP derived NPCs (NPC-WT-EGFP), and H9^{OE-NPC} cells (NPC-OE1 and NPC-OE2). Equal amounts of cells were seeded. Cy5 fluorescence (Y-axis) is proportional to peptide synthesis. SD values refer to 3 independent experiments. ns: not significant. *: P≤0.05, **: P≤0.01, ***:P≤0.001, ****:P≤0.0001 (Welch’s unpaired t-test).

C: Polysome profiles for H9^{WT} (WT, black), H9^{52KO} (52-KO1, red), and H9^{NPC} cells (NPC, blue). Average values from three independent experiments. The Y-axis depicts the absorption at A260, the X-axis the time of flow-through.

1449 **Supplementary Figure 8: Identification of transcriptional and translational differences**
1450 **between H9^{WT} and H9^{52KO} cells by ribosome profiling.**

1451

1452 A: Percentage of reads mapping to 5' untranslated regions (5' UTR), coding sequences (CDS),
1453 or 3' untranslated regions (3' UTR) of protein-coding genes, for each replicate sequencing
1454 library of H9^{WT} (WT) and H9^{52KO} (52KO) cell lines. Both total RNA (left) and ribosome
1455 protected fragment (RPF, right) derived reads are shown.

1456

1457 B: Periodicity of ribosome protected fragment (RPF) reads mapped to mRNA transcripts.
1458 Metagene analysis shows normalized mean counts, at single-nucleotide resolution,
1459 representing ribosome P-site occupancy relative to start (left) and stop (right) codons from
1460 H9^{WT} (WT, black) or H9^{52KO} cells (KO, red) libraries ($n = 3$ libraries from individual cultures).
1461 Number of transcripts analyzed after extreme outlier removal is given by 'n'.

1462

1463 C: Correlation between reads mapped per mRNA transcript in total RNA and RPF libraries in
1464 H9^{WT} (WT) and H9^{52KO} (KO) ($n = 3$ libraries from individual cultures). Normalized (CPM)
1465 mean counts are plotted. Color scale indicates plotting density. 'n' denotes number of
1466 transcripts analyzed. Spearman's rho and associated P value (algorithm AS 89) are shown.

1467

1468 D: Left: mRNA transcripts displaying altered expression level (Log₂FC mRNA) in H9^{52KO}
1469 (KO) compared to H9^{WT} (WT) as measured by analysis of read counts mapped to mRNA
1470 transcripts derived from total RNA libraries. Those changing significantly between conditions
1471 are colored (cyan).

1472 Right: differential ribosome occupancy on mRNA transcripts in H9^{52KO} compared to H9^{WT}
1473 cells. Log₂ fold-change in read counts derived from analysis of RPF libraries (Log₂FC RPF)
1474 and corresponding -Log₁₀ of Benjamini-Hochberg P^{adj} values are plotted. Transcripts
1475 changing significantly between conditions are colored (purple). 'n' denotes total number of
1476 transcripts analyzed. The number of transcripts showing reduced (DN) or increased (UP)
1477 translation is also shown.

1478

1479 E: Gene ontology analysis of mRNA transcripts displaying upregulated expression in H9^{52KO}
1480 cells compared to H9^{WT} cells. Top 10 GO categories (FDR < 0.05) for biological processes are

1481 listed. Number of genes overlapping with each biological process GO category is indicated by
1482 the color scale gradient (count).

1483

1484 F: Gene ontology analysis of mRNA transcripts displaying decreased translation (ribosome
1485 occupancy) but not transcription (translation only) in H9^{52KO} cells compared to H9^{WT}. Top 10
1486 GO categories (FDR < 0.05) for biological process are labelled. Number of genes overlapping
1487 with each biological process GO category is indicated by the color scale gradient (count).

1488

1489

1490

1491

1492

1493

1494

1495

1496

1497

1498 **Supplementary Figure 9: Analysis of the potential molecular mechanisms underlying**
1499 **differential translation by wild-type and SNPRD52 KO cells.**

1500

1501 A: Complement to Figure 6C and D, 3 more experimental repeats. Left: Detection of total
1502 cellular and ribosome-bound FMRP protein by Western Blot in H9^{WT} (WT), H9^{52KO} (KO),
1503 H9^{52OE} (OE), H9^{NPC} (NPC WT), and H9^{52OE-NPC} (NPC OE) cells. IP (input) = whole cell lysate,
1504 RC (ribosome cushion) = ribosomes purified by sucrose cushion. Vinculin serves as a control
1505 for appropriate separation of input and purified ribosomes, RPL4 and RPS18 for normalization
1506 to ribosome abundance. Right: Quantification of the enrichment of FMRP in the ribosome-
1507 bound fraction based on western blots (left). Bands were quantified, then subsequently the
1508 values for FMRP normalized to the corresponding ribosomal protein (RPL4 or RPS18), and
1509 finally the ratio of the ribosome-bound fraction over the input fraction calculated.

1510

1511

1512

1513

1514

1515

1516

1517

1518

1519

1520

1521

1522

1523

1524

1525

1526

1527

1528

1529

1530

1531

1532 **SUPPLEMENTARY TABLES**

1533

1534

1535 **SUPPLEMENTARY TABLE 1**

1536

1537 rRNA positions displaying statistically significant 2'-O-me changes during mouse cortex
1538 development. RMS values for individual libraries (replicates), average RMS values (mean
1539 RMS Score), and corresponding standard deviations (SD RMS score) are listed.

1540 Δ RMS refers to the difference in RMS score between the maximal (MAX) and minimal (MIN)
1541 average RMS values of the series. The p-value was calculated by a two-tailed Welch's t-test
1542 (assuming unequal variance). The cutoff for Δ RMS is >0.15 and the positions are ranked by p-
1543 value.

1544

1545 **SUPPLEMENTARY TABLE 2**

1546

1547 rRNA positions with statistically significant differences in RMS score (as defined for
1548 Supplementary Table 1) between four brain regions (cortex CTX, olfactory bulb OFB,
1549 cerebellum CBM, and hippocampus HPC) in neonates (P0).

1550

1551 **SUPPLEMENTARY TABLE 3**

1552

1553 rRNA positions with statistically significant differences in RMS score (as defined for
1554 Supplementary Table 1) between four brain regions (cortex CTX, olfactory bulb OFB,
1555 cerebellum CBM, and hippocampus HPC) in adult mice.

1556

1557 **SUPPLEMENTARY TABLE 4**

1558

1559 rRNA positions with statistically significant differences in RMS score (as defined for
1560 Supplementary Table 1) between adult mice and neonates (P0) in four brain regions (cortex
1561 CTX, olfactory bulb OFB, cerebellum CBM, and hippocampus HPC).

1562

1563 **SUPPLEMENTARY TABLE 5**

1564

1565 rRNA positions with statistically significant differences in RMS score (as defined for
1566 Supplementary Table 1) between H9^{WT} hESCs and their differentiated progeny respectively
1567 (ectoderm, endoderm, mesoderm).

1568

1569 **SUPPLEMENTARY TABLE 6**

1570

1571 List of rRNA positions considered to be true potentially 2'-O-methylated positions in this
1572 article for mouse and human based on RMS and MassSpec evidence. The numbering is based
1573 on the snoRNABase (snorna.biotoul.fr).

1574

1575 **SUPPLEMENTARY TABLE 7**

1576

1577 Ribosome-associated peptides identified by mass spectrometry from H9^{WT} hESCs, H9^{52KO}, and
1578 H9^{eNPC} cells as well as either 80S monosomes or polysomes and compared two by two.

1579

1580 **SUPPLEMENTARY TABLE 8**

1581

1582 Peptides described in Supplementary Table 8, filtered by a list of true ribosome associated
1583 proteins (Supplementary Table 9).

1584

1585 **Supplementary Table 9**

1586

1587 List of true ribosome associated proteins described by Imami et al.

1588

1589 **Supplementary Table 10**

1590

1591 List of canonical transcripts representing each protein-coding gene selected from the
1592 GRCh38, v97 Ensembl annotation file.

1593

1594

1595

1596

1597

1598

1599 **Methods**

1600

1601 **Cell culture**

1602

1603 *Human embryonic stem cell (hESC) and induced pluripotent stem cell (iPSC) culture*

1604

1605 H9 and HUES4 cells were grown under feeder-free conditions on plates coated with hESC-
1606 qualified Matrigel (Corning Life Sciences, #354277) in mTeSRTM1 medium (Stem Cell
1607 Technologies, #85850). Medium changes were performed daily. Cells were passaged about
1608 every three days using 1X TrypLETM Select (Life Technologies, #12563-011) when reaching
1609 80-90% confluence.

1610 Upon thawing, Rock inhibitor (Y-27632) (LC laboratories, #Y-5301) was added at a final
1611 concentration of 10 μ M. Cells were frozen in half mTeSRTM1 medium and half FBS-20%
1612 DMSO (final DMSO concentration: 10%).

1613 KOLF2 iPS cells were grown under feeder-free conditions on Matrigel-coated plates in
1614 TeSRTM-E8TM (Stem Cell Technologies, #05990).

1615

1616 *Generation of neural progenitor cells*

1617

1618 H9 hESCs were differentiated into early neural progenitor cells (eNPCs) with STEMdiffTM
1619 Neural Induction Medium (Stem Cell Technologies, #05835) following the manufacturer's
1620 instructions for the monolayer protocol variant. In brief, H9 cells were plated on Matrigel-
1621 coated plates at a density of 2x10⁶ cells per cm in neural induction medium supplemented with
1622 10 μ M Rock inhibitor. Medium was changed every day and the cells passaged after about a
1623 week. After two more passages in neural induction medium, the cells were transferred into
1624 STEMdiffTM Neural Progenitor Medium (Stem Cell Technologies, #05833) for expansion and
1625 freezing.

1626

1627 *Long-term neural differentiation*

1628

1629 H9-derived NPCs were further differentiated into late neural progenitor cells (INPCs, or neural
1630 precursors, according to the manufacturer) by plating them at 125.000 cells/cm² on Matrigel
1631 and growing the cells in STEMdiffTM Neuron Differentiation Kit (Stem Cell Technologies,
1632 #08500) medium for one week with daily medium changes.

1633 After one week, the cells were dissociated and plated at a density of 3×10^4 cells/cm in
1634 STEMdiff™ Neuron Maturation Kit (Stem Cell Technologies, #08510) medium on a double
1635 layer of poly-L-ornithine (Sigma-Aldrich #P3655) at $15 \mu\text{g/mL}$ in PBS and laminin (Sigma-
1636 Aldrich, #L2020) at $5 \mu\text{g/mL}$ in DMEM/F-12. The medium was changed every second day and
1637 the cells kept in culture up to 52 days.

1638

1639 *Neural progenitor cell maintenance*

1640

1641 H9 hESC-derived early neural progenitor cells (eNPCs) were grown on Matrigel (Corning Life
1642 Sciences, #354277) in STEMdiff™ Neural Progenitor Medium (Stem Cell Technologies,
1643 #05833).

1644 Cells were passaged around every five days at 80-90% confluence using Accutase (Stem Cell
1645 Technologies, #07920) for detaching and DMEM/F-12 + GlutMAX (Invitrogen, #31331-028)
1646 for resuspension, and frozen in STEMdiff™ Neural Progenitor Freezing Medium (Stem Cell
1647 Technologies, #05838).

1648

1649 *Directed ES differentiation into the three embryonic germ layers*

1650

1651 HUES4, H9, and KOLF2 iPS cells were differentiated into ecto-, endo-, and mesoderm using
1652 the STEMdiff™ Trilineage Differentiation Kit (Stem Cell Technologies, #05230) according to
1653 the manufacturer's instructions.

1654 In brief, ES cells were plated on day 0 in technical triplicates in Matrigel-coated 6-well plates
1655 in either mTeSR™1 (HUES4, H9) or TeSR™-E8™ medium (KOLF2 iPS) supplemented with
1656 $10 \mu\text{M}$ Rock inhibitor for endo- and mesoderm differentiation at 2.10^6 cells per well for
1657 endoderm and $0.5.10^6$ cells per well for mesoderm. Cells destined for ectoderm differentiation
1658 were directly plated in ectoderm differentiation medium on day 0, supplemented with $10 \mu\text{M}$
1659 Rock inhibitor, at a density of 2.10^6 cells per well. On day 1, medium was switched to the
1660 respective germ layer differentiation medium and changed on a daily basis until day 5 for endo-
1661 and mesoderm differentiation, and day 7 for ectoderm differentiation. Bright field images were
1662 taken every day and cells from every day of differentiation analyzed by RT-qPCR and
1663 immunohistochemistry.

1664

1665

1666

1667 **RNA isolation from mouse brains**

1668

1669 CD-1 mice were sacrificed at embryonic stages E11, E12.5, E14, E15.5, E17, P0 (neonates)
1670 and 6-7 months (adult). The brains were dissected in ice cold PBS in a cold room and snap-
1671 frozen on dry ice. RNA was extracted using TRIZOL-LS according to the manufacturer's
1672 instructions.

1673

1674 **RiboMeth-Seq**

1675

1676 RiboMeth-seq library construction and sequencing were performed as previously described
1677 (Birkedal et al., 2014; Krogh et al., 2016). Triplicate libraries were produced for each cell line
1678 or condition analyzed, and grown to ~70–80% confluence before collection. A portion of 5 µg
1679 of total RNA was used for input. RNA was partially degraded in alkali at denaturing
1680 temperatures. The 20–40-nucleotide fragments were purified by PAGE and linkers added using
1681 a system relying on a modified *Arabidopsis* tRNA ligase joining 2',3'-cyclic phosphate and 5'-
1682 phosphate ends. The libraries were sequenced on the Ion Proton platform using Ion PI Chip Kit
1683 v.3 (Life Technologies).

1684

1685

1686 **RiboMeth-seq Data treatment**

1687

1688 Data was analyzed as previously reported (Birkedal et al., 2014; Krogh et al., 2016). Briefly,
1689 sequencing reads were mapped to a corrected human rRNA reference sequence. To facilitate
1690 comparison with other studies, we have used the human rRNA sequence numbering according
1691 to snoRNABase throughout this study (snorna.biotoul.fr). An alignment table of these rRNA
1692 sequences is provided in Krogh and Jansson et al, 2016 (Krogh et al., 2016). The RiboMeth-
1693 seq score (RMS score) represents the fraction of molecules methylated at each nucleotide
1694 position, and is calculated by comparing the number of read-end counts at the queried position
1695 to six flanking positions on either side. Quantifications are performed in mouse on 41 sites in
1696 18S, 66 in 28S and 2 in 5.8S and in human on 41 sites in 18S, 68 in 28S and 2 in 5.8S
1697 respectively, for which both RMS plus mass spectrometry evidence exists, and are reliably
1698 detected in at least one of cell lines examined in this study (Supp. Table 6). As to facilitate

1699 comparison, the human numbering is used both for mouse and human samples. The
1700 equivalence between mouse and human sites can be found in [Supplementary Table 6](#).

1701

1702 Statistically significant differences in RMS signatures between two cell lines or conditions
1703 were determined by pairwise comparison ($p < 0.05$, two-tailed unpaired Welch's t test and ≥ 0.15
1704 difference in RMS score).

1705 Heat-map representations were produced using the pheatmap function in R.

1706

1707 RMS data has been deposited to Gene Expression Omnibus (GEO), accession: **GSE205022**

1708

1709

1710 **Generation of loss and gain of function mutants**

1711

1712 *Generation of SNORD52 knock-out clones by CRISPR-Cas9*

1713

1714 Two guides (sgRNAs) encompassing the human SNORD52 gene were designed:
1715 GGAGTGGACGTTAGAAAGGG and GGATACTGGGTCTCCAGAA.

1716 Both sgRNAs were cloned into pX335 and pX458 plasmids respectively. The plasmids were
1717 co-transfected into H9 hESC cells using the Amaxa 4D nucleofector (#AAF-1003B and #AAF-
1718 1003X) and the P3 Primary Cell 4D-Nucleofector X kit (Lonza, #V4XP-3024).

1719 48h after transfection, the cells were single-cell sorted into Matrigel-coated 96-well plates for
1720 double GFP/Crimson fluorescence by FACS. Rock inhibitor (Y-27632) was added to mTESR-
1721 1 medium until the second medium change.

1722 After about two weeks, colonies became visible and were screened for successful deletion
1723 using standard PCR (forward primer: CTCCCAGTGGAGCTGTTCTC, reverse primer:
1724 GGGGGAGATTCCAAACCTTA), the GoTaq Green master mix (Promega, #M7122), and running
1725 the amplification products on a 1% Agarose gel.

1726 Candidate clones were further verified by DNA sequencing and expanded. A few CRISPR-
1727 negative clones – showing no deletion of SNORD52 but having undergone otherwise the exact
1728 same procedure – were also expanded and tested alongside the two SNORD52 KO clones.

1729

1730 *Generation of SNORD52 overexpression clones*

1731

1732 The SNORD52 gene sequence was cloned into an artificial intron and placed into a 2-exon
1733 EGFP sequence derived from pGINT (courtesy to Cristian Bellodi), subsequently used to
1734 replace the intron-less EGFP of the AAVS1-targeting vector pAAV-PuroCAG-EGFP obtained
1735 from Ludovic Vallier.

1736 Following the protocol described in Bertero et al. (Bertero et al., 2016), the EGFP-SNORD52
1737 construct was targeted to the AAVS1 safe harbor locus in H9 hESCs *via* zinc finger nucleases.
1738 As a control, the original pAAV-PuroCAG-EGF construct was used.

1739 H9 hESCs were transfected with the Amaxa 4D Nucleofector. The cells were expanded for a
1740 few days, allowing for the elimination of transient transfection, then single cell FACS-sorted
1741 for GFP fluorescence. Correct insertion of the construct into the AAVS1 locus was verified by
1742 DNA sequencing, and SNORD52 expression by RT-qPCR.

1743

1744 **Gene expression**

1745

1746 *RNA isolation*

1747

1748 Total RNA preparation was performed using QIAzol (Qiagen) and chloroform according to
1749 the protocol from the manufacturer. Concentrations were measured using a NanoDrop, and
1750 RNA quality assessed with a BioAnalyser.

1751

1752 *cDNA generation and RT-qPCR*

1753

1754 Reverse-transcription to cDNA was achieved with the TaqManReverse Transcription Kit
1755 (Applied Biosystems, #N80803234) according to the manufacturer's recommendations.
1756 Typically, 1µg of RNA was used per reverse transcription reaction.

1757 RT-qPCR analyses were performed in technical triplicates on a StepOnePlus™ Real-Time
1758 PCR System (Thermo Fisher Scientific, #4376600) in a 96-well format and using the Fast
1759 SYBR Green Master Mix (Thermo Fisher Scientific, #4385612). 2µL of cDNA were combined
1760 with 5µL of Fast SYBR Green Master Mix, 0.3µL of forward or reverse primer at 100µM, and
1761 2.4µL nuclease-free water per well.

1762

1763 List of primers used in the study:

1764

Gene	Forward primer	Reverse primer
BRACHYURY/T	CCTTCAGCAAAGTCAAGCTCACC	TGAACTGGGTCTCAGGGAAGCA
CDX2	TGGAGCTGGAGAAGGAGTTT	CTGCTGCTGCTGTTGCTG
CER1	CTTCTCAGGGGGTCATCTTG	TCCCAAAGCAAAGGTTGTTC
CXCR4	CACCGCATCTGGAGAACCA	GCCCATTTCCTCGGTGTAGTT
DLK1	TCCTGAAGGTGTCCATGAAAG	GTGGTTGTAGCGCAGGTTG
DNMT3B	GAATTACTCACGCCCAAGGA	ACCGTGAGATGTCCCTCTTGTC-
EN1	CGTGGCTTACTCCCCATTTA	TCTCGCTGTCTCTCCCTCTC
EOMES	AAATGGGTGACCTGTGGCAAAGC	CTCCTGTCTCATCCAGTGGGAA
FABP7	TGTGACCAAACCAACGGTAAT	CTTTGCCATCCCATTCTGTA
FOXA1	GGGGGTTTGTCTGGCATAGC	GCACTGGGGGAAAGGTTGTG
FOXA2	AGGAGGAAAACGGGAAAGAA	CAACAACAGCAATGGAGGAG
FOXG1	TGGCCCATGTCGCCCTTCT	GCCGACGTGGTGCCGTTGTA
GAD67	CTCCTGGGGGCGCCATATCCAA	CCAGTTTAGGCACAGCCGCCAT
GATA4	ACACCCCAATCTCGATATGTTTG	GTTGCACAGATAGTGACCCGT
GATA6	AGGGCTCGGTGAGTCCAAT	CGCTGCTGGTGAATAAAAAGGA
GBX2	GTTCCCGCCGTCGCTGATGAT	GCCGGTGTAGACGAAATGGCCG
HAND1	ATGGACGTGCTGGCCAAGGATG	TTAACTCCAGCGCCCAGACTTGC
HES5	CCGGTGGTGGAGAAGATG	TAGTCCTGGTGCAGGCTCTT
HHEX	CACCCGACGCCCTTTTACAT	GAAGGCTGGATGGATCGGC
HNF1B	AGAGGGAGGTGGTCGATGTC	AGCTGATCCTGACTGCTTTTG
HNF4A	CAGGCTCAAGAAATGCTTCC	GGCTGCTGTCTCATAGCTT
HOXA1	GTACGGCTACCTGGGTCAAC	ACTTGGGTCTCGTTGAGCTG
HOXA2	CGTCGCTCGCTGAGTGCCTG	TGTCGAGTGTGAAAGCGTCGAGG
KDR	AAAGACTACGTTGGAGCAATCCCT	CTGGATTGTGTACACTCTGTCAAA
LEFTY1	ACCTTGGGGACTATGGAGCT	GCTCTCCAGTGGCCAAAGAT
LHX2	GAAGGGGCGGCCGAGGAAAC	GCTGGTCACGGTCCAGGTGC
LMX1A	CGCATCGTTTCTTCTCCTCT	CAGACAGACTTGGGGCTCAC
MAP2	CCACCTGAGATTAAGGATCA	GGCTTACTTTGCTTCTCTGA
MEF2C	AGATACCCACAACACACCACGCGCC	ATCCTTCAGAGAGTCGCATGC
NANOG	CAAAGGCAAACAACCCACTT	TCTGCTGGAGGCTGAGGTAT
NESTIN	GGGAAGAGGTGATGGAACCA	AAGCCCTGAACCCTCTTTGC
NGN2	ATCCGAGCAGCACTAACACG	GCACAGGCCAAAGTCACAG
OCT4	CGAAAGAGAAAGCGAACCAG	AACCACACTCGGACCACATC
OTP	GAGTCCCGAGTGCAGGTCTGGT	GCACGGAACACGTTGGTCGTCT
OTX2	CTTACGCAGTCAATGGGCTGAG	CGAGTGAACGTGTCCTCTC
PAX6	TGGTATTCTCTCCCCCTCCT	TAAGGATGTTGAACGGGCAG
PAX7	CTTCAGTGGGAGGTCAGGTT	CAAACACAGCATCGACGG
SALL4	TGCAGCAGTTGGTGGAGAAC	TCGGTGGCAAATGAGACATTC
SERT	TGGACCCTCCATTCCACGTCCC	GTCTGGAGCCCCTTAGACCGG

SIX3	ACCGGCCTCACTCCCACACA	CGCTCGGTCCAATGGCCTGG
SNAIL	GCCTAGCGAGTGGTTCTTCT	TAGGGCTGCTGGAAGGTA
SNORD52	GGGAATGATGATTTACAGACT	TTTTGACATCATGACCAGCA
SOX1	GGGAAAACGGGCAAATAAT	TTTTGCGTTCACATCGGTTA
SOX10	CTTTCTTGTGCTGCATACGG	AGCTCAGCAAGACGCTGG
SOX17	AAGGGCGAGTCCCGTATC	TTGTAGTTGGGGTGGTCTG
SOX2	ACACCAATCCCATCCACACT	CCTCCCAGGTTTTCTCTGT
SOX9	AGGAAGCTCGCGGACCAGTAC	GGTGGTCCTTCTTGTGCTGCAC
TBR1	TCGTCCCCGCTCAAGAGCGA	CCTTGCGCAGTTCTTCTCGCA
TBX6	AGGCCCGCTACTTGTCTTCTG	TGGCTGCATAGTTGGGTGGCTCTC
TDGF1	ACAGAACCTGCTGCCTGAAT	ATCACAGCCGGGTAGAAATG
VGLUT1	AATAACAGCACGCCACCGCG	AGCCGTGTATGAGGCCGACAGT
WNT1	GAGCCACGAGTTTGGATGTT	TGCAGGGAGAAAGGAGAGAA
WNT3A	GCGATGGCCCCACTCGGATACT	TAGCTGCCAGAGCCTGCTTCA

1765

1766

1767 *Immunofluorescence*

1768

1769 Cells were plated in Lab-Tek Chamber slides (Sigma Aldrich, #C7182) at the densities
 1770 corresponding to the relevant protocol, washed with PBS and fixed for 15 minutes at RT with
 1771 4% paraformaldehyde, followed by three PBS washes and potential storage in PBS at 4°C.

1772 Fixed cells were permeabilized for 10 minutes in PBS, 0.1% Triton, then incubated for 1h in
 1773 blocking buffer (PBS, 5% FBS). Primary antibodies were diluted in blocking buffer at the
 1774 indicated dilutions and left overnight at 4°C under gentle shaking, then washed off by applying
 1775 PBS 3 times for 10 minutes. Secondary antibodies were diluted at a 1:1000 dilution in blocking
 1776 buffer and left for 1h at room temperature. Slides were subsequently washed 3 times with PBS
 1777 for 10 minutes and mounted in Duolink in situ mounting medium with DAPI (Sigma-Aldrich,
 1778 #DUO82020-5ML).

1779 Images were acquired with a Zeiss Axio Imager.M2 microscope (#490020-0004-000) and
 1780 images analyzed with the open-source ImageJ software (Fiji).

1781

1782 List of primary antibodies:

1783

Target	Provider	Reference	Host	Isotype	Working dilution
OCT4	Stem Cell Technologies	#60093	Mouse	IgG2b, kappa	1:1000
PAX6	Stem Cell Technologies	#60094	Rabbit	IgG, polyclonal	1:500

ZO1	BD Biosciences	#610966	Mouse	IgG1	1:500
TUJ1	Stem Cell Technologies	#60092	Mouse	IgG2a	1:500
MAP2	Abcam	#ab112667	Mouse	IgG1	1:500
NESTIN	Stem Cell Technologies	#60091	Mouse	IgG1, kappa	1:2000
OTX2	Abcam	#ab21900	Rabbit	IgG, polyclonal	1:500
TTR	BioRad	#AHP1837	Sheep	IgG, polyclonal	1:500
SOX17	R&D Systems	#AF1924	Goat	IgG, polyclonal	1:400
T/BRACHYURY	R&D Systems	#AF2085	Goat	IgG, polyclonal	1:200
Beta-catenin	Cell Signaling	#9587	Rabbit	IgG, polyclonal	1:500

1784

1785

1786 List of secondary antibodies:

1787

Antibody	Provider
Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488	Thermo Scientific
Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 594	Thermo Scientific
Donkey anti-Goat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 594	Thermo Scientific
Donkey Anti-Sheep IgG H&L (Alexa Fluor® 594)	Abcam
Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488	Thermo Scientific
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 594	Thermo Scientific

1788

1789

1790 **Western Blotting**

1791 *Normal Western Blot*

1792 Western blotting was performed as previously described (Jansson et al., 2015). The following
 1793 antibodies were used:

1794

Target	Provider	Reference	Host	Isotype	Working dilution
RECK	Cell Signaling	#3433	Rabbit	Monoclonal	1:1000
CITED1	Merck	#424M-17	Mouse	Monoclonal	1:500
Vinculin	Sigma Aldrich	#V9131	Mouse	Monoclonal	1: 100 000
FMRP	Cell Signaling	#4317	Rabbit	Polyclonal	1:1000
RPL4	Santa Cruz Biotechnology	#sc-100838	Mouse	Monoclonal	1:1000
RPS18	Nordic Biosite	#LS-C162774-400	Rabbit	Polyclonal	1:1000

1795

1796

1797 *Ribosome isolation by sucrose cushion followed by Western Blot*

1798

1799 **3D modelling**

1800

1801 Modelling performed using MacPyMol (Version 2.1 INTEL-12.10.12) on the structure 4UG0
1802 (<https://www.rcsb.org/structure/4UG0>) published by Khatter et al. (Khatter et al., 2015).

1803 for the FMRP part:

1804 Structure published by Chen et al. (Chen et al., 2014).

1805 Accession number: EMD-5806 on <http://emsearch.rutgers.edu>.

1806

1807 **Ribosome profiling**

1808 *Ribosome profiling*

1809

1810 Ribosome Profiling was performed essentially as previously described (Ingolia et al., 2009),
1811 following the protocol given in TruSeq Ribo Profile Mammalian (Illumina), with minor
1812 modifications. Three individual replicates for each of the two cell lines were collected. A single
1813 15cm dish corresponding to one replicate was harvested at a time. For each replicate, cell media
1814 was aspirated and cells washed with ice-cold PBS. No cycloheximide pre-treatment was
1815 performed. After thorough removal of the PBS, the dish was fully immersed in liquid nitrogen
1816 and placed on dry ice. For cell lysis, 1mL of 1x Mammalian Lysis Buffer (Illumina) containing
1817 100 µg/mL cycloheximide was added dropwise to the dish which was then placed on wet ice.
1818 Cells were then scraped off to the lower portion of the dish and allowed to thaw in the lysis
1819 buffer. Lysate was homogenized by pipetting and triturated ten times through a 25-gauge
1820 needle. The lysate was then transferred to a DNA LoBind 1.5mL microfuge tube (Eppendorf)
1821 and incubated on ice for 5min. The lysate was cleared by centrifugation at 20000g, 4°C for
1822 10min and the supernatant transferred to a fresh microfuge tube. Aliquots were prepared for
1823 each replicate, flash-frozen in liquid nitrogen and stored at -80°C until further use. The steps
1824 detailed in TruSeq Ribo Profile Mammalian protocol (Illumina) were followed to generate total
1825 RNA and ribosome protected fragment (RPF) RNAseq libraries corresponding to the 3
1826 individual replicates from each of the two cell lines. For RPF libraries, following nuclease
1827 digestion, monosomes were purified using illustra MicroSpin S-400 HR Columns. Ribo-
1828 Zero™ Gold Kit (Illumina) was used to deplete ribosomal rRNA. The libraries prepared from
1829 total RNA or RPF for both conditions were pooled and sequenced on a NextSeq® 500 System
1830 (Illumina).

1831

1832 *Ribosome Profiling data analysis*

1833

1834 The sequencing data was demultiplexed using Illumina bcl2fastq. Quality of the sequencing
1835 files were controlled with fastqc. Adaptor sequences were removed with cutadapt. Reads
1836 derived from RPF and total RNA were aligned to human rRNA and tRNA sequences with
1837 bowtie2 (v2.2.9) and the mapped reads discarded. The remaining reads were aligned to
1838 GRCh38.p12 (Ensembl v.97) with STAR. Reads mapping to Human Genome Organisation
1839 (HUGO) approved genes were used for downstream analyses. RPF read lengths were analysed
1840 for trinucleotide periodicity using Ribotaper. RPF reads with lengths between 29 to 34
1841 nucleotides were selected and the optimal P-site offset was defined as position 12 from 5' read
1842 ends. RPF read alignment files were filtered with samtools to retain only 29 to 31nt read
1843 lengths, no read length filtering was applied to the total RNA alignment files. A single
1844 canonical transcript representing each protein-coding gene was selected from the
1845 GRCh38, v97 Ensembl annotation file ([Supp. Table 10](#)). FeatureCounts was used to
1846 generate counts of primary reads mapping to exons of these transcripts for both total RNA and
1847 RPF. RPF reads with ribosome P-site positions mapping within transcript coding-region
1848 sequences (CDS) were again counted using FeatureCounts, and along with the mRNA exons
1849 mapped reads, used for further measurements of differential translation and mRNA expression.
1850 Ribosomal Investigation and Visualization to Evaluate Translation (RIVET) 49, was used for
1851 translation and expression analysis of the representative transcripts (similar results were
1852 obtained for gene-level analysis). No fold-change cut-offs were directly applied, in order to
1853 additionally detect more subtle changes in translation. Regulated transcripts were therefore
1854 nominally identified by statistical significance. Translation regulation categories were defined
1855 according to RIVET, based on mRNA expression and ribosome occupancy, derived from
1856 normalized total RNA read counts or RPF read counts mapping to protein-coding mRNA
1857 transcripts, respectively (Supplementary Table 2). Plots from the resulting RIVET output files
1858 were generated using the ggplot2 package in R. The RNA sequencing data has been deposited
1859 to GEO, accession: **GSE199387**.

1860

1861

1862 *Gene ontology and gene-set enrichment analysis*

1863

1864 All Gene ontology (GO) analyses of ribosome profiling was performed using the WebGestalt
1865 using the over-representation test against GO biological process database (Liao et al., 2019).

1866

1867

1868 *Metagene analysis.*

1869

1870 For metagene analyses, bam files containing exon-mapped reads for each library were

1871 converted to normalized reads per kilobase per million (RPKM) or counts per million reads

1872 (CPM) single-nucleotide resolution coverage bigwig files, with bamCoverage from the

1873 deepTools suite⁶⁰. WiggleTools⁶¹ (Ensembl) and wigToBigWig (Encode, kentUtils) were

1874 then used to merge these and create mean coverage files per condition. These were input to

1875 deepTools computeMatrix, together with an annotation file containing the exon coordinates for

1876 the selected mRNA transcripts. For RPF coverage over all transcripts, a count matrix was then

1877 generated for library RPKM RPF coverage over the coding regions (CDS), scaled to size 100

1878 nt, flanked by unscaled regions before and

1879 after the translation start (TSS) and end (TES) sites. For further analysis, the scaled coverages

1880 of transcripts comprising the different translationally regulated categories were extracted from

1881 this matrix and median values at each position plotted. For average ribosome occupancy, CPM

1882 normalization was used and offset applied using bamCoverage, so as to use only the nucleotide

1883 position representing the ribosome P-site for each read as the signal (see ‘Ribosome profiling

1884 data analysis’, above). The P-site coverage files were input to computeMatrix and a count

1885 matrix generated for -30 to +330 or -330 to +30 nucleotides, relative to the CDS start or end

1886 site respectively for each transcript (unscaled). The resulting counts at each position were

1887 divided by the total RPF count in CDS for each corresponding transcript to give the average

1888 ribosome occupancy per nucleotide position in each transcript. The mean values at each

1889 equivalent nucleotide position relative to the translation start site were plotted after extreme

1890 outlier removal (>3x interquartile range), no smoothing was applied. For P-site CPM the same

1891 matrices were used, although here the counts at each position were summed at each nucleotide

1892 position. For plotting, extreme outliers (>3x interquartile range) were removed. Plots were

1893 produced using ggplot2 in R.

1894

1895 **Polysome profiling**

1896 Cells at 70-80% confluency were incubated with 100 µg/mL cycloheximide (Sigma Aldrich)

1897 for 3 min., washed once, and harvested by scraping in PBS containing 100 µg/mL

1898 cycloheximide. Cells were lysed at 4°C for 10 min in polysome buffer (20 mM Tris-HCl (pH

1899 7.5), 150 mM KCl, 5 mM MgCl₂) supplemented with 0.5% NP40 (Igepal CA-630, Sigma
1900 Aldrich), 2 mM DTT, 100 µg/mL cycloheximide, Protease Inhibitor Cocktail (cOmplete
1901 EDTA free, Roche), and murine RNase inhibitor (NEB). The cell lysate was cleared for
1902 membranes by centrifugation at 12.000g for 15 min. at 4°C. Cleared lysates were normalized
1903 according to NanoDrop UV spectrophotometer measurements (Thermo Scientific) and layered
1904 onto a 7% - 47% (w/v) linear sucrose gradient (Sigma BioUltra) in polysome buffer. Gradients
1905 were centrifuged at 35.000 g for 3h at 4°C in an ultracentrifuge using the SW40ti rotor head
1906 (Beckman). Fractions of 1 mL were collected from the top at 1 mL/min. while continuously
1907 measuring A₂₅₄ using a Brandel Tube Piercer (Brandel) and the BioLogic LP system (BioRad).
1908

1909 **Global nascent peptide synthesis assay**

1910 Global novel protein synthesis was assessed using the Click-iT Plus OPP Protein Synthesis
1911 Assay Kit (Life Technologies, #C10456 for green fluorescence, #C10457 for red fluorescence
1912 given that the overexpression clones are constitutively expressing EGFP) according to the
1913 manufacturer's protocol.
1914

1914

1915 **TOP/FOP Wnt reporter assay**

1916

1917 The M50 Super 8x TOPFlash (Addgene #12456) and M51 Super 8x FOPFlash (Addgene,
1918 #12457) were transfected together with a pRLTK (Renilla) plasmid using the Mirus2020
1919 transfection reagent (MirusBio, #MIR 5404) according to the supplier's protocol in a 12-well
1920 plate format in technical triplicates.

1921 Cells were prepared for Luciferase and Renilla measurements using the Dual-Glo Luciferase
1922 Assay System (Promega, #E2920) according to the manufacturer's instructions. Luminescence
1923 readings were carried out on a GloMax Multi Detection System (Promega). Luciferase readings
1924 were normalized to the corresponding Renilla values.
1925

1925

1926 **Northern blotting analysis of rRNA processing**

1927 Total RNA (7.5 µg) was separated on a formaldehyde denaturing 1% agarose gel and
1928 transferred to a BrightStar-Plus membrane (Ambion) using capillary blotting. followed by UV
1929 cross-linking. The probes (10 pmol each) were radiolabelled with [γ -³²P]ATP using T4 PNK
1930 (Thermo Scientific) and hybridized to the membrane overnight in hybridization buffer

1931 (4× Denhardt’s solution, 6× SSC, 0.1% SDS) at T_m of the probe of -10 °C. The membrane
1932 was subsequently washed four times in 3× SSC supplemented with 0.1% SDS, followed by
1933 exposure to a propidium iodide screen and scanned on a Typhoon scanner (GE Healthcare).

1934

1935 **Mass spectrometry on 80S and polysomes**

1936 Proteins from polysome profile fractions containing 80S ribosomes and polysomes
1937 respectively, were precipitated with 20% Trichloroacetic Acid and washed three times in ice
1938 cold acetone. Protein pellets were solubilized using 100 µl of lysis buffer (50 mM HEPES (pH
1939 8.5), 6 M guanidinium hydrochloride, 10 mM TCEP, 40 mM CAA). Samples were boiled at
1940 95°C for 5 min., after which they were sonicated on high for 5×30 sec. in a Bioruptor sonication
1941 water bath (Diagenode) at 4°C. After determining protein concentration with Bradford (Sigma),
1942 10 µg was taken forward for digestion. Samples were diluted 1:3 with 10% Acetonitrile, 50
1943 mM HEPES pH 8.5, LysC (MS grade, Wako) was added in a 1:50 (enzyme to protein) ratio,
1944 and samples were incubated at 37°C for 4 hrs. Samples were further diluted to 1:10 with 10%
1945 Acetonitrile, 50 mM HEPES (pH 8.5), trypsin (MS grade, Promega) was added in a 1:100
1946 (enzyme to protein) ratio and samples were incubated overnight at 37°C. Enzyme activity was
1947 quenched by adding 2% trifluoroacetic acid (TFA) to a final concentration of 1%. Prior to
1948 TMTPro labeling, the peptides were desalted on in-house packed C18 Stagetips (Rappsilber et
1949 al., 2007). For each sample, 2 discs of C18 material (3M Empore) were packed in a 200ul tip,
1950 and the C18 material activated with 40 µl of 100% Methanol (HPLC grade, Sigma), then 40 µl
1951 of 80% Acetonitrile, 0.1% formic acid. The tips were subsequently equilibrated 2× with 40 µl
1952 of 1% TFA, 3% Acetonitrile, after which 10 µg of sample was loaded using centrifugation at
1953 4,000 rpm. After washing the tips twice with 100 µl of 0.1% formic acid, the peptides were
1954 eluted into clean 500 µl Eppendorf tubes using 40% Acetonitrile, 0.1% formic acid. The eluted
1955 peptides were concentrated in an Eppendorf Speedvac, and re-constituted in 50 mM HEPES
1956 (pH 8.5) for TMTPro labeling. For normalization, an equimolar peptide mix from all the
1957 samples was generated by mixing equal amounts from each sample, that could subsequently
1958 act as a normalization spike-in. Labeling was done according to manufacturer’s instructions,
1959 and subsequently, labeled peptides were mixed 1:1:1:1:1:1:1:1:1:1:1 (13-plex, 12 samples
1960 + 1 normalization spike-in), acidified to 1% TFA and Acetonitrile concentration brought down
1961 to <5% using 2% TFA. Prior to mass spectrometry analysis, the peptides were fractionated
1962 using an offline ThermoFisher Ultimate3000 liquid chromatography system using high pH
1963 fractionation (5mM Ammonium Bicarbonate, pH 10) at 5 µl/min flowrate. 10 µg of peptides

1964 were separated over a 70 min. gradient (5% to 35% Acetonitrile), while collecting fractions in
1965 204 sec. intervals. The resulting 20 fractions were pooled into 10 final fractions and vacuum
1966 concentrated to dryness. Fractions were resuspended in 1% TFA, 2% Acetonitrile for MS
1967 analysis.

1968

1969 **MS data acquisition**

1970 For each fraction, peptides were loaded onto a C18 trap cartridge (ThermoFisher 160454),
1971 connected in-line to a 50 cm C18 reverse-phase analytical column (Thermo EasySpray ES803)
1972 using 100% Buffer A (0.1% Formic acid in water) at 5 μ l/min., using the Ultimate3000 HPLC
1973 system. After trap loading, the sample loop was switched out of the flowpath, and peptides
1974 were eluted over a 90 min. method ranging from 8% to 60% of Buffer B (80% acetonitrile,
1975 0.1% formic acid) at 200 nl/min.. The Orbitrap Fusion instrument (Thermo Fisher Scientific)
1976 was run in an SPS MS3 top speed method with FAIMSPro ion mobility enabled (2 CVs, -50V
1977 and -70V). Full MS spectra were collected at a resolution of 120,000, with an AGC target of
1978 100% or maximum injection time of 50 ms and a scan range of 400–1600 m/z. The MS2
1979 spectra were obtained in the ion trap operating at turbo speed, with an AGC target value of
1980 1×10^4 or maximum injection time of 35 ms, a normalised CID collision energy of 35 and an
1981 intensity threshold of $5e3$. Dynamic exclusion was set to 60 s, and ions with a charge state <2 ,
1982 >6 or unknown were excluded. From the resulting MS2 scan, 10 precursors were selected for
1983 SPS-MS3 analysis, fragmented with a normalised HCD collision energy of 55, and ions
1984 collected for a maximum of 118 ms or AGC target of 250%. Resulting MS3 spectra were
1985 collected at 60,000 resolution and scan range of 100-500 for reporter ion quantification.
1986 FAIMS CVs were switched on the fly, with 1.5 s cycle time dedicated to each CV. MS
1987 performance was verified for consistency by running complex cell lysate quality control
1988 standards, and chromatography was monitored to check for reproducibility.
1989 The mass spectrometry data have been deposited to the ProteomeXchange Consortium
1990 (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository with the
1991 dataset identifier **PXD035621**.

1992

1993 **TMT Quantitative Proteomics Analysis**

1994 The raw files were analyzed using Proteome Discoverer 2.4. TMT SPS-MS3 quantitation was
1995 enabled in the processing and consensus steps, and spectra were matched against the 9606
1996 Human database obtained from UniProt. Dynamic modifications were set as Oxidation (M),

1997 Deamidation (N,Q) and Acetyl on protein N-termini. Cysteine carbamidomethyl and TMTPro
1998 were set as static modifications on peptide N-termini and Lysine residues. All results were
1999 filtered to a 1% FDR, and protein quantitation done using the built-in Minora Feature Detector.

2000

2001 **Proteomic mass spectrometry data analysis**

2002

2003 All MS spectra were searched in Proteome Discoverer 2.4 (ThermoFisher), using the
2004 SEQUEST algorithm against the human proteome Uniprot database (containing its reversed
2005 complement and known contaminants). Spectral matches were filtered to false discovery rate
2006 (FDR) <0.01, using the target-decoy strategy combined with linear discriminant analysis.
2007 Proteins were quantified only from peptides with an Average Reporter S/N Threshold of 10,
2008 and co-isolation specificity of 0.75.

2009 To examine only those proteins most likely to be truly ribosome associated, thus eliminating
2010 proteins likely to be contaminants throughout the sucrose gradients, identified proteins were
2011 filtered against a compiled list of previously identified high confidence 40S/60S interacting
2012 proteins *REF1* (Supp. Table 9).

2013 Statistical analyses of protein abundance changes were performed using the DEqMS pipeline
2014 for TMT labelled MS data (<https://github.com/yafeng/DEqMS>) *REF2*, with $q.value < 0.05$.
2015 Log₂FC changes in protein abundance were determined to be significant at $sca.adj.pval$
2016 (Benjamini-Hochberg method adjusted DEqMS p-values) <0.05 (Supp. Table 7, Supp. Table
2017 8). The abundance values scaled to the reference channel (pooled sample) output from
2018 Proteome Discoverer were used as input.

2019 Volcano plots for each comparison were generated using the ggplot2 package in R. Bar charts
2020 were generated in Graphpad Prism using DEqMS normalized abundances and statistical
2021 significance was tested using two-tailed unpaired Welch's *t* test.

2022 The mass spectrometry data have been deposited to the ProteomeXchange Consortium, via the
2023 PRIDE repository with the dataset identifier **PXD035621**.

2024




Figure 1





Figure 2






Figure 4




Figure 5






Figure 6




Supplementary Figure 1




Supplementary Figure 2


A




Supplementary Figure 3




Supplementary Figure 4




Supplementary Figure 5




Supplementary Figure 6





Supplementary Figure 8

A



Supplementary Figure 9